Erlotinib HCl (OSI-744)

Name: Erlotinib HCl (OSI-744)
Brand: Selleck Chemicals
SKU: S1023
Rating: 5 (420 reviews)

For research use only.

Catalog No.S1023 Synonyms: CP358774, NSC 718781

420 publications

Erlotinib HCl (OSI-744) Chemical Structure

CAS No. 183319-69-9

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

Selleck's Erlotinib HCl (OSI-744) has been cited by 420 publications

Cell, 2019, 178(4):807-819.e21

PubMed: 31398338 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Gastroenterology, 2019, 156(6):1788-1804

PubMed: 30641053 ( click the link to review the publication )

Cell Metab, 2019, 30(3):525-538

PubMed: 31303424 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):807-822

PubMed: 30423298 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(1):91-106

PubMed: 28457749 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2013, 3(12):1404-15

PubMed: 24065731 ( click the link to review the publication )

Cell Metab, 2013, 17(6):1000-8

PubMed: 23707073 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Genet, 2012, 44(8):852-60

PubMed: 22751098 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e202004229

PubMed: 33443570 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108647

PubMed: 33472066 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009216

PubMed: 33481911 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Exp Ther Med, 2021, 21(1):9

PubMed: 33235618 ( click the link to review the publication )

Oncol Lett, 2021, 21(1):44

PubMed: 33262836 ( click the link to review the publication )

Mol Ther Oncolytics, 2021, 20:364-372

PubMed: 33614917 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-00409-1

PubMed: 32958903 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1792

PubMed: 32286289 ( click the link to review the publication )
Nat Commun, 2020, 10;11(1):2935

PubMed: 32523045 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107840

PubMed: 32610141 ( click the link to review the publication )

Mucosal Immunol, 2020, 4

PubMed: 32132671 ( click the link to review the publication )

Oncogene, 2020, 39(15):3163-3178

PubMed: 32051553 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(1) pii: E173

PubMed: 31936715 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):66

PubMed: 32552913 ( click the link to review the publication )

Cells, 2020, 17;9(4) pii: E1003

PubMed: 32316635 ( click the link to review the publication )

Cancer Discov, 2020, CD-19-1262

PubMed: 32513774 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19;molcanther10362019

PubMed: 32430488 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371586 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 11(19):5746-5757

PubMed: 32913468 ( click the link to review the publication )
Transl Res, 2020, S1931-5244(20)30257-7

PubMed: 33197651 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

Eur J Pharm Biopharm, 2020, S0939-6411(20)30305-2

PubMed: 33068736 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0420

PubMed: 33028660 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:585292

PubMed: 33194732 ( click the link to review the publication )

Front Oncol, 2020, 10:1593

PubMed: 33014812 ( click the link to review the publication )

J Cell Sci, 2020, jcs.238840

PubMed: 32546532 ( click the link to review the publication )

J Cell Mol Med, 2020, 22

PubMed: 32441057 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(2)

PubMed: 31940844 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9307

PubMed: 33291316 ( click the link to review the publication )

Sci Rep, 2020, 13;10(1):4722

PubMed: 32170113 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):959

PubMed: 31969600 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.014960

PubMed: 33273014 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxins (Basel), 2020, 12(12)E753

PubMed: 33260619 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4453-4460

PubMed: 32606939 ( click the link to review the publication )

Mol Med, 2020, 26(1):66

PubMed: 32611363 ( click the link to review the publication )

BMC Cancer, 2020, 4;20(1):375

PubMed: 32366230 ( click the link to review the publication )

Cancer Res Treat, 2020, 10.4143/crt.2020.585

PubMed: 33070556 ( click the link to review the publication )
Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0227261

PubMed: 31914141 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:10983-10994

PubMed: 33149613 ( click the link to review the publication )

Thorac Cancer, 2020, 11

PubMed: 32525282 ( click the link to review the publication )

Chin Med, 2020, 15:66

PubMed: 32612672 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Am Soc Nephrol, 2020, ASN.2019111215

PubMed: 32616537 ( click the link to review the publication )

Neurooncol Adv, 2020, 2(1):vdaa067

PubMed: 32642717 ( click the link to review the publication )

Cancer Metab, 2020, 8:19

PubMed: 32974013 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Oncotarget, 2020, 11(46):4224-4242

PubMed: 33245718 ( click the link to review the publication )

J Pharmacol Toxicol Methods, 2020, 106895

PubMed: 32629158 ( click the link to review the publication )

Pharmaceutics, 2020, 12(2)

PubMed: 32028611 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Gastroenterology, 2019, 156(6):1788-1804

PubMed: 30641053 ( click the link to review the publication )

Small, 2019, 15(33):e1900309

PubMed: 31245925 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )
Cancer Res, 2019, 79(9):2220-2231

PubMed: 30890618 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3341-3351

PubMed: 30796031 ( click the link to review the publication )

Clin Cancer Res, 2019, 1;25(19):5866-5877

PubMed: 31431454 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):211

PubMed: 31118055 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Anal Chem, 2019, 91(15):10026-10032

PubMed: 31282657 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):282

PubMed: 30910997 ( click the link to review the publication )

Br J Cancer, 2019, 120(3):306-316

PubMed: 30585254 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1565-1576

PubMed: 31270152 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Oncogenesis, 2019, 8(12):70

PubMed: 31772161 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(4):1002-1012

PubMed: 30635434 ( click the link to review the publication )

Front Oncol, 2019, 9:461

PubMed: 31214503 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Sci Rep, 2019, 9(1):845

PubMed: 30696915 ( click the link to review the publication )
Sci Rep, 2019, 9(1):2357

PubMed: 30787334 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Biol Chem, 2019, 294(27):10530-10543

PubMed: 31126985 ( click the link to review the publication )

J Biol Chem, 2019, 294(21):8336-8347

PubMed: 30979723 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:4254759

PubMed: 30863451 ( click the link to review the publication )

Respir Res, 2019, 20(1):270

PubMed: 31791326 ( click the link to review the publication )

Mol Imaging Biol, 2019, 21(4):696-704

PubMed: 30377939 ( click the link to review the publication )

J Ethnopharmacol, 2019, 239:111928

PubMed: 31077779 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Dev Biol, 2019, 10.1016/j.ydbio.2019.10.006

PubMed: 31610144 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

PLoS One, 2019, 14(9):e0214901

PubMed: 31539380 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):2729-2736

PubMed: 30854046 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2719-2729

PubMed: 31911857 ( click the link to review the publication )

Spectrochim Acta A Mol Biomol Spectrosc, 2019, 10.1016/j.saa.2019.117737

PubMed: 31757706 ( click the link to review the publication )

JCI Insight, 2019, 10.1172/jci.insight.127552

PubMed: 31237864 ( click the link to review the publication )

Immunity, 2018, 49(1):134-150

PubMed: 29958800 ( click the link to review the publication )

J Exp Med, 2018, 215(1):115-140

PubMed: 29191914 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

PLoS Biol, 2018, 16(9):e2006624

PubMed: 30261040 ( click the link to review the publication )

PLoS Biol, 2018, 16(12):e2006660

PubMed: 30543635 ( click the link to review the publication )

Cell Syst, 2018, 6(3):343-354

PubMed: 29428415 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4344-4359

PubMed: 29844121 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )
Mol Cancer, 2018, 17(1):50

PubMed: 29455661 ( click the link to review the publication )

Int J Cancer, 2018, 143(8):1994-2007

PubMed: 29756386 ( click the link to review the publication )

Int J Cancer, 2018, 142(1):156-164

PubMed: 28906000 ( click the link to review the publication )

Cancer Lett, 2018, 436:1-9

PubMed: 30118839 ( click the link to review the publication )

Cancer Lett, 2018, 434:152-159

PubMed: 30036610 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

J Pathol, 2018, 244(2):242-253

PubMed: 29160922 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):31

PubMed: 29458405 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):684

PubMed: 29880898 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):219

PubMed: 29440633 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2018, 11:455-467

PubMed: 29858080 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2018, 12:817-828

PubMed: 30153566 ( click the link to review the publication )

Stem Cells, 2018, 36(8):1273-1285

PubMed: 29726088 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(3):957-971

PubMed: 29843133 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11):2297-2308

PubMed: 30093568 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):732-739

PubMed: 29467274 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

MAbs, 2018, 10(7):1003-1017

PubMed: 30130447 ( click the link to review the publication )
Cell Biol Toxicol, 2018, 34(6):459-469

PubMed: 29478126 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):2063-2073

PubMed: 29701925 ( click the link to review the publication )

Cancer Sci, 2018, 109(8):2391-2400

PubMed: 29927028 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(12):2419-2435

PubMed: 30662801 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Lung Cancer, 2018, 122:44-53

PubMed: 30032844 ( click the link to review the publication )

J Cell Physiol, 2018, 233(9):6975-6983

PubMed: 29336487 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386292 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(6):3073-3085

PubMed: 29575527 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Toxicol Sci, 2018, 166(2):394-408

PubMed: 30496568 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 29933569 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3317

PubMed: 29463831 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Gene, 2018, 642:95-102

PubMed: 29133145 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 59(6):695-705

PubMed: 30011381 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:565-581

PubMed: 29606890 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:887-897

PubMed: 29740218 ( click the link to review the publication )

Int J Oncol, 2018,

PubMed: 30226590 ( click the link to review the publication )

Int J Oncol, 2018, 53(2):527-538

PubMed: 29845246 ( click the link to review the publication )
Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):249

PubMed: 29506489 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):191

PubMed: 29448920 ( click the link to review the publication )

Cancer Med, 2018, 7(1):208-218

PubMed: 29239135 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(5):829-838

PubMed: 30167846 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:5499-5508

PubMed: 30233210 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:3087-3100

PubMed: 29872320 ( click the link to review the publication )

Curr Cancer Drug Targets, 2018, 18(3):278-286

PubMed: 28359236 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1292-1299

PubMed: 29885023 ( click the link to review the publication )

Mol Med Rep, 2018, 17(2):2509-2514

PubMed: 29207200 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):935-943

PubMed: 30074936 ( click the link to review the publication )

Acta Haematol, 2018, 140(1):30-39

PubMed: 30071517 ( click the link to review the publication )

Pharmazie, 2018, 73(11):630-634

PubMed: 30396380 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

JCI Insight, 2018, 3(11)

PubMed: 29875309 ( click the link to review the publication )

Biologics, 2018, 12:75-86

PubMed: 30154647 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12020-12034

PubMed: 29552290 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )
Oncotarget, 2018, 9(79):34996-35007

PubMed: 30405889 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29568372 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(5):518-529

PubMed: 28414315 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Nat Commun, 2017, 8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1420

PubMed: 29127277 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Autophagy, 2017, 13(3):579-591

PubMed: 28103122 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(14):3769-3780

PubMed: 28174235 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cancer Res, 2017, 77(2):579-589

PubMed: 27671677 ( click the link to review the publication )

J Control Release, 2017, 262:58-71

PubMed: 28694030 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.27388

PubMed: 28980940 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.33173

PubMed: 29087937 ( click the link to review the publication )
Elife, 2017, 10.7554/eLife.20444

PubMed: 28195529 ( click the link to review the publication )

Oncogene, 2017, 36(48):6747-6748

PubMed: 29188822 ( click the link to review the publication )

Oncogene, 2017, 36(47):6542-6554

PubMed: 28759046 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e2980

PubMed: 28796259 ( click the link to review the publication )

Cell Death Dis, 2017, 8(9):e3033

PubMed: 28880262 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):357-364

PubMed: 27913578 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Oncol, 2017, 11(8):1065-1077

PubMed: 28486761 ( click the link to review the publication )

Mol Oncol, 2017, 11(6):670-681

PubMed: 28388009 ( click the link to review the publication )

Mol Oncol, 2017, 11(6):628-639

PubMed: 28306189 ( click the link to review the publication )

Radiother Oncol, 2017, 124(3):504-512

PubMed: 28823407 ( click the link to review the publication )

Cancer Sci, 2017, 108(1):53-60

PubMed: 27783866 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):915-928

PubMed: 28289161 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29156644 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28572590 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16763

PubMed: 29196706 ( click the link to review the publication )

Sci Rep, 2017, 7:45136

PubMed: 28332584 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1669

PubMed: 28490807 ( click the link to review the publication )
Clin Lung Cancer, 2017, 18(3):281-285

PubMed: 28038979 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(10)

PubMed: 28265001 ( click the link to review the publication )

Respir Res, 2017, 18(1):52

PubMed: 28340578 ( click the link to review the publication )

Phytomedicine, 2017, 36:59-67

PubMed: 29157829 ( click the link to review the publication )

Int J Oncol, 2017, 50(6):2049-2058

PubMed: 28440469 ( click the link to review the publication )

Cell Biosci, 2017, 7:43

PubMed: 28852468 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(4):915-926

PubMed: 28052650 ( click the link to review the publication )

Pancreas, 2017, 46(4):575-581

PubMed: 28196025 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Biosci Rep, 2017, 37(3)

PubMed: 28507201 ( click the link to review the publication )

Environ Toxicol, 2017, 32(5):1628-1636

PubMed: 28101945 ( click the link to review the publication )

PLoS One, 2017, 12(12):e0189087

PubMed: 29253018 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Clin Exp Nephrol, 2017, 10.1007/s10157-017-1386-9

PubMed: 28176019 ( click the link to review the publication )

Oncol Lett, 2017, 14(3):3445-3454

PubMed: 28927099 ( click the link to review the publication )

J Vis Exp, 2017, 126

PubMed: 28829429 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317709639

PubMed: 28714370 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

JCO Precis Oncol, 2017, 1:PO.16.00019

PubMed: 32913967 ( click the link to review the publication )

Gels, 2017, 3(3)

PubMed: 30920523 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317709639

PubMed: 28714370 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109068-109078

PubMed: 29312591 ( click the link to review the publication )
Oncotarget, 2017, 8(41):70736-70751

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98771-98781

PubMed: 29228726 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Cancer Metab, 2017, 5:6

PubMed: 28852500 ( click the link to review the publication )

Oncotarget, 2017, 8(13):20961-20973

PubMed: 28423495 ( click the link to review the publication )

Oncotarget, 2017, 8(62):105479-105491

PubMed: 29285266 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63014-63025

PubMed: 28968967 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111333-111345

PubMed: 29340057 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73745-73756

PubMed: 29088741 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29163770 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423495 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Am Soc Nephrol, 2016, 27(10):3105-3116

PubMed: 27694161 ( click the link to review the publication )

PLoS Pathog, 2016,

PubMed: 27711202 ( click the link to review the publication )

Cell Death Dis, 2016,

PubMed: 27685624 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27207775 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )
Sci Rep, 2016, 6:32809

PubMed: 27609096 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )

Int J Oncol, 2016, 48(5):1855-67

PubMed: 26936292 ( click the link to review the publication )

J Drug Target, 2016, 25(2):125-131

PubMed: 27633093 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51922-51933

PubMed: 27409162 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59809-59819

PubMed: 27494858 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27680026 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51922-51933

PubMed: 27409162 ( click the link to review the publication )

Oncotarget, 2016, 8(52):89552-89565

PubMed: 29163770 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26551-66

PubMed: 27034169 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015,

PubMed: 26195767 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2005

PubMed: 25744720 ( click the link to review the publication )

Cancer Prev Res (Phila), 2015, 8(9):765-76

PubMed: 26100522 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29483

PubMed: 25688715 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25659577 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.03.014

PubMed: 25779676 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26538233 ( click the link to review the publication )
Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

J Biol Chem, 2015,

PubMed: 26152725 ( click the link to review the publication )

BMC Genomics, 2015, 16 Suppl 12:S2

PubMed: 26681397 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Cancer Chemoth Pharm, 2015, 10.1007/s00280-015-2751-6

PubMed: 25907508 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140782

PubMed: 26474061 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )

Anal Biochem, 2015, 10.1016/j.ab.2015.01.016

PubMed: 25659657 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25686822 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9206-19

PubMed: 25826078 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25576915 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14329-43

PubMed: 25869210 ( click the link to review the publication )

Oncotarget, 2015, 9(38):24914-24926

PubMed: 29861842 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )
Oncotarget, 2015,

PubMed: 26486084 ( click the link to review the publication )

J Hepatol, 2014, 60(1):143-51

PubMed: 23978713 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(13):3613-22

PubMed: 24803578 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(15):4047-58

PubMed: 24895459 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 10.1089/ars.2013.5304

PubMed: 24684506 ( click the link to review the publication )

Sci Signal, 2014, 7(338):ra75

PubMed: 25118327 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(9):2203-14

PubMed: 25028470 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):152-60

PubMed: 24954871 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

J Transl Med, 2014, 12(1):265

PubMed: 25240937 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):649-663

PubMed: ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 351(2):352-8

PubMed: 25187431 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

J Mol Endocrinol, 2014, 52(2):223-34

PubMed: 24463098 ( click the link to review the publication )

Oncol Res, 2014, 21(3):137-44

PubMed: 24512728 ( click the link to review the publication )

BMC Microbiol, 2014,

PubMed: 25471819 ( click the link to review the publication )
PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Histochem Cell Biol, 2014, 10.1007/s00418-014-1223-0

PubMed: 24824474 ( click the link to review the publication )

Biores Open Access, 2014, 3(4):176-82

PubMed: 25126481 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(24):6842-52

PubMed: 24130071 ( click the link to review the publication )

Cell Rep, 2013, 4(4):764-75

PubMed: 23972990 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

BRIT J CANCER, 2013, 109(8):2155-66

PubMed: 24045666 ( click the link to review the publication )

Lung Cancer, 2013, 81(3):354-61

PubMed: 23769318 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(1):864-70

PubMed: 23299479 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62104

PubMed: 23690929 ( click the link to review the publication )

Laser in Surg Med, 2013, 45(7):460-8

PubMed: 24037824 ( click the link to review the publication )

Head Neck, 2013, 35(1):86-93

PubMed: 22495823 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23896512 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(1):9-17

PubMed: 23946753 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

J Clin Invest, 2012, 122(9):3197-210

PubMed: 22886302 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Cancer, 2012, 118(21):5198-209

PubMed: 22510844 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )
Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(10):e48532

PubMed: 23119048 ( click the link to review the publication )

Oncogene, 2011, 30(22):2547-57

PubMed: 21278786 ( click the link to review the publication )

Mol Cancer Ther, 2011, 10(10):1846-56

PubMed: 21768330 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Microvasc Res, 2011, 81(1):135-42

PubMed: 21067705 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(4):577-86

PubMed: 20097731 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Case Western Reserve University, 2010, Zhang Z

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

Targets

HER1/EGFR ^[1]
(Cell-free assay)

2 nM

In vitro

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells. ^[1] Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. ^[2] Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. ^[3] The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. ^[4] Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human SKBR3 cells	MoDySpVv[3Srb36gZZN{[Xl?			NG\RXlJKdmirYnn0bY9vKG:oIFjFVlIhcW5iaIXtZY4hW0uEUkOgZ4VtdHNiYomgTHRTTiCjc4PhfUwhUUN3ME2xMlg6KM7:TT6=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQThzNUSxNkc,OTl6MUW0NVI9N2F-
human A431 cells	NEXGeHFHfW6ldHnvckBie3OjeR?=			M4q5OmlvcGmkaYTpc44hd2ZiRVfGVkBqdiCqdX3hckBCPDNzIHPlcIx{KGK7IFjUVmYh[XO\|YYmsJGlEPTB;MD60NkDPxE1w	NWDo[VJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NVU1OTJpPkG5PFE2PDF{PD;hQi=>
A431	MWPGeY5kfGmxbjDhd5NigQ>?			MXjJcohq[mm2aX;uJI9nKEWJRmKgbY4hcHWvYX6gRVQ{OSClZXzsd{BjgSCyaH;zdIhwfHm{b4PpcoUhTUyLU1GgZZN{[XluIFnDOVAhRSByLkCwNVIh\|ryPLh?=	Mny4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
MCF7	MYPDfZRwfG:6aXPpeJkh[XO\|YYm=			M{LpNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNuIFnDOVAhRSByLkCwNVIh\|ryPLh?=	Mn\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
A431	MVLGeY5kfGmxbjDhd5NigQ>?		NHjQWZc3OCCvaX7z	M1XE[2lvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCjY4TpeoF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgdJJmfHKnYYTl[EBnd3JiNkCgcYlveyCob3zsc5dm\CCkeTDFS2Yh[WSmaYTpc44h[W6mIH3lZZN2emWmIHHmeIVzKDFyIH3pcpMh[nliRVzJV2EtKEmFNUCgQUAxNjByMUKg{txONg>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OEi2PUc,OzByOUi4Olk9N2F-
A431	M33VbmZ2dmO2aX;uJIF{e2G7		NID6VFY3OCCvaX7z	NEnDPZBKdmirYnn0bY9vKG:oIFXHSnIhcW5iaIXtZY4hSTR\|MTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTUeIIHnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhPjBibXnud{Bnd2yub4fl[EBjgSCHR1[gZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDFUGlUSSCvZYToc4QtKEmFNUCgQUAxNjByMUKg{txONg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh7NEW4PUc,Ojd6OUS1PFk9N2F-
A431	MmfBSpVv[3Srb36gZZN{[Xl?		M{j6bFYxKG2rboO=	NX3wXZBwUW6qaXLpeIlwdiCxZjDFS2ZTKGmwIHj1cYFvKEF2M{GgZ4VtdHNiY3;tdI92dmRicILleJJm[XSnZDDmc5IhPjBibXnuJIJm\m:{ZTDFS2Yhe3SrbYXsZZRqd25iZn;yJFExKG2rboOgZpkheGixc4Doc5R6em:\|aX7lJGVNUVODIHP5eI9jdG:2IH3leIhw\CxiSVO1NEA:KDBwMECxNkDPxE1w	MkX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEK1NVkoRjJ3OEiyOVE6RC:jPh?=
HCC827	NGXrV3FEgXSxdH;4bYNqfHliYYPzZZk>		MYi0PEBpenN?	NH\ISGlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS0N6MkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMECyJO69VS5?	M1vHNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFMxLz5{NEmwNFg{ODxxYU6=
PC9	M2GzSWZ2dmO2aX;uJIF{e2G7		NULGTW91OiCqcoO=	Mn[zTY5pcWKrdHnvckBw\iCHR1\SJIV5d25iMUmg[IVt\XSrb36gZYN1cX[jdHnu[{BufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGDDPUBk\WyuczDh[pRmeiB{IHjyd{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCwOVkh\|ryPLh?=	NX7XSIV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|A6QTRpPkKzPVMxQTl2PD;hQi=>
NCI-H292	NILRW21HfW6ldHnvckBie3OjeR?=		M3zSXlEhcHJ?	MYLJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF7DTU1JOjl{IHPlcIx{KHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDmc4xtd3enZDDifUB{fGmvdXzheIlwdiC5aYToJGVITiCob4KgPEBucW6\|IHL5JIVt\WO2cn;jbIVucWy3bXnu[ZNk\W62IHntcZVvd2G\|c3H5MEBKSzVyIE2gNE4xODZ\|IN88UU4>	NIP1UFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS1OVkyQSd-Mk[0OVU6OTl:L3G+
HCC827	MnjOSpVv[3Srb36gZZN{[Xl?		MofONkBpenN?	NX61V\|huUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbHX0bY9vKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDh[pRmeiB{IHjyd{BjgSC\|YX7ke4lkcCCHTFnTRUwhUUN3MDC9JFAvODB6IN88UU4>	NXnJenBVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
MCF7	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXG0PEBpenN?	NVTFXIQ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAyKM7:TT6=	NGnrRY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxOFg{Pyd-MUm5NVQ5Ozd:L3G+
H3255	MVnGeY5kfGmxbjDhd5NigQ>?		M3GzVlIhcHK\|	NF6zNoZKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKgcZV1[W62IHH1eI9xcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTFMzPTViY3XscJMh[W[2ZYKgNkBpenNiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkCxJO69VS5?	NVmwUGY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
H3255	MV7GeY5kfGmxbjDhd5NigQ>?		NHrYdXQzKGi{cx?=	NF33[ZlKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKgcZV1[W62IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKM{K1OUBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IFXHSkB{fGmvdXzheIlwdiCob4KgNVAhdWmwczDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNFEh\|ryPLh?=	M{X2eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mki3O\|MxLz5{OEK4O\|c{ODxxYU6=
PC9	NH7UO25HfW6ldHnvckBie3OjeR?=		NXPQOHFLOiCqcoO=	MUnJcohq[mm2aX;uJI9nKEWJRmKg[IVt\XSrb36gcZV1[W62IHH1eI9xcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVGM6KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IIPhcoR4cWOqIFXMTXNCNCCLQ{WwJF0hOC5yMUGg{txONg>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
A549	M4DESmZ2dmO2aX;uJIF{e2G7		M3XnclIhcHK\|	M3i2OGlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQhf2muZD30fZBmKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG1OFkh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDFS2Yhe3SrbYXsZZRqd25iZn;yJFExKG2rboOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlAyOSEQvF2u	NEPSRVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4O\|c{OCd-MkiyPFc4OzB:L3G+
PC9	Mk\ISpVv[3Srb36gZZN{[Xl?		M3OzTFIhcHK\|	MmfzTY5pcWKrdHnvckBw\iCHR1\SJIV5d25iMUmg[IVt\XSrb36gcZV1[W62IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCSQ{mgZ4VtdHNicILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSCHR1[gd5RqdXWuYYTpc44h\m:{IEGwJI1qdnNiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkCxNUDPxE1w	MoS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEe3N\|AoRjJ6Mki3O\|MxRC:jPh?=
A549	MoTHSpVv[3Srb36gZZN{[Xl?			M1SwSWlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQhf2muZDD0fZBmKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckBmgHC{ZYPz[YQhcW5iaIXtZY4hSTV2OTDj[YxteyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwMEGxJO69VS5?	M3rCcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
BA/F3	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=			MoLCR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUIH31eIFvfCxiSVO1NEA:KDBwMEGyOUDPxE1w	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ\|OUKyPUc,OTl{M{myNlk9N2F-
KB	Mki4SpVv[3Srb36gZZN{[Xl?		NX\ieGFpOSCqch?=	MoH0TY5pcWKrdHnvckBw\iCHR1[td5RqdXWuYYTl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIFXHSnIhcW5iaIXtZY4hU0JiY3XscJMhcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJJRwKEWJRjDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiNjDtbY5{KGK7IFXMTXNCNCCLQ{WwJF0hOC5yMUmg{txONg>?	NH;BZYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVEzOyd-MkS0NVEyOjN:L3G+
NIH3T3	MmC1SpVv[3Srb36gZZN{[Xl?			MUTJcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25iaX6gUmlJO1R\|IHPlcIx{NCCLQ{WwJF0hOC5yMUmzJO69VS5?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjR6MEK4OEc,OTZ2OECyPFQ9N2F-
MCF7	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFWw[Jc1QCCqcoO=	NVv0e4xuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NFKwcmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxOFg{PSd-MUm5NVQ5OzV:L3G+
Sf9	MkLaSpVv[3Srb36gZZN{[Xl?			M2[2e2lvcGmkaYTpc44hd2ZiY3zvcoVlKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOtbY5n\WO2ZXSgV4Y6KGOnbHzzJIJ6KHOxbHnkMZBp[XOnIFXMTXNCNCCLQ{WwJF0hOC5yMjFOwG0v	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizO{c,OTl7MUS4N\|c9N2F-
MCF7	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1K5VlQ5KGi{cx?=	M{X2PWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	M4XW[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEC1NVE3Lz5{MECwOVEyPjxxYU6=
MCF7	MnfORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEPPVpc1QCCqcoO=	Ml;VRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyJO69VS5?	M2S0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUm0PFU6Lz5{MEW5OFg2QTxxYU6=
MCF7	NWG1UoNbSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUe0PEBpenN?	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEKg{txONg>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5N{W4PEc,OjJ{N{e1PFg9N2F-
A16-F10	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYC0PEBpenN?	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEFzNj3GNVAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFIh\|ryPLh?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFzMkW0NUc,OjJzMUK1OFE9N2F-
MCF7	NVPiVnB1S3m2b4TvfIlkcXS7IHHzd4F6		NVTiRpd[PDhiaILz	MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NFS1ZpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwNlI6OCd-MkG4NFIzQTB:L3G+
MCF7	NF;zTWdEgXSxdH;4bYNqfHliYYPzZZk>		NU\WR4VZPDhiaILz	MoizR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xOiEQvF2u	NIjkWYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yO\|U6Pyd-MkC2Nlc2QTd:L3G+
HT-29	M4TPRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{O2b\|Q5KGi{cx?=	NF3FSoFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCyJO69VS5?	NYHLWlQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PTZpPkK5OFA4QTV4PD;hQi=>
MCF7	Mn;hRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4O4NVQ5KGi{cx?=	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEKg{txONg>?	NWDKVnJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOFU5ODJpPkKzNlQ2QDB{PD;hQi=>
HCC827	NIjCToxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3XNXFczKGi{cx?=	M2HTSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDPFI4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFAvODJ7IN88UU4>	NYHwfIg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0PFc6OTdpPkK2OFg4QTF5PD;hQi=>
Sf9	MUTGeY5kfGmxbjDhd5NigQ>?			NWLBSo1VUW6qaXLpeIlwdiCxZjDjcI9v\WRiRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{1qdm[nY4Tl[EBU\jliY3XscJMh[nlic3;sbYQueGijc3WgSWxKW0FuIFnDOVAhRSByLkCzJO69VS5?	NYjtbIJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVQ5OzVpPkG5PVE1QDN3PD;hQi=>
Sf9	NXrJW2RDTnWwY4Tpc44h[XO\|YYm=		MnHINUBpeg>?	NX;M[WFCUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDIbZM3gC22YXfn[YQhTUeIUjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhOSCqcjDifUBGVEmVQTygTWM2OCB;IECuNFMh\|ryPLh?=	M3fFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUm0PFU6Lz5{MEW5OFg2QTxxYU6=
Sf9	NGS5ZZNHfW6ldHnvckBie3OjeR?=		NWfWXVZoOSCqch?=	M4LsbmlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIFXHSnIh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFTFUGZKSS:2aX3lMZJme2:udnXkJIZtfW:{aX3leJJ6KGG\|c3H5MEBKSzVyIE2gNE4xOyEQvF2u	NXXC[2xDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|c2QDhpPkKyNlc4PTh6PD;hQi=>
Sf9	M3T4[mZ2dmO2aX;uJIF{e2G7		MUmxNEBucW6\|	NX7BO\|FJUW6qaXLpeIlwdiCxZjDFS2ZTKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBifXSxcHjvd5Bpd3K7bHH0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOTBibXnud{Bu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFTFUGZKSS:WaX3lMXJme2:udnXkJGZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yMzFOwG0v	NISzV3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGxNlU1OSd-MkKxNVI2PDF:L3G+
Sf9	M3fWb2Z2dmO2aX;uJIF{e2G7		NEPTUlgyKGi{	NH\YVIVKdmirYnn0bY9vKG:oIHjpd5Rq\GmwZT30ZYdo\WRiaIXtZY4hemWlb33ibY5idnRiY4n0c5Bt[XOvaXOg[I9u[WmwIH;mJGVITlJiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBU\jliY3XscJMh[W[2ZYKgNUBpeiCkeTDESWxHUUFxdHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLkCzJO69VS5?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4MUK3Nkc,OjJ\|NkGyO\|I9N2F-
Sf9	NVnYW243TnWwY4Tpc44h[XO\|YYm=		NEW3cooyKGi{	NHPDOFdKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGVITlJiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDj[YxteyCjZoTldkAyKGi{IHL5JGRGVE[LQT;0bY1mNXKnc3;seoVlKG[udX;ybY1mfHK7IHHzd4F6NCCLQ{WwJF0hOC5yMzFOwG0v	M3LIeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{[zNVQ5Lz5{MUe2N\|E1QDxxYU6=
Sf9	MV;GeY5kfGmxbjDhd5NigQ>?		Ml2zNUBpeg>?	M2rWe2lvcGmkaYTpc44hd2ZiSHnzMZRi\2enZDDFS2ZTKGW6cILld5Nm\CCrbjDpcpNm[3RiU3[5JINmdGy\|IHHmeIVzKDFiaIKgZpkhfGmvZT3y[ZNwdH[nZDDmcJVwemmvZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjB\|IN88UU4>	NGfSU2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixOlUyPyd-MkG4NVY2OTd:L3G+
Sf9	M3ywSWZ2dmO2aX;uJIF{e2G7			NULFcWxiUW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIILlZ49u[mmwYX70JGVITlJiYYX0c5Bpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGK7IIPvcIllNXCqYYPlJGVNUVODLDDJR\|UxKD1iMD6wN{DPxE1w	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{N{W5O{c,OjB4Mke1PVc9N2F-
MIAPaCa2	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2XoWVQ5KGi{cx?=	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCPSVHQZWNiOiClZXzsd{Bi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCzJO69VS5?	M2nISlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVU3Lz5{OUSwO\|k2PjxxYU6=
MCF7	NH;DUHhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFW5SFc1QCCqcoO=	MlW5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB\|IN88UU4>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m1Okc,Ojl2MEe5OVY9N2F-
PC3	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXu0PEBpenN?	MkLFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODNizszNMi=>	M3zyc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVU3Lz5{OUSwO\|k2PjxxYU6=
Sf9	M1v0dmZ2dmO2aX;uJIF{e2G7			MlvMTY5pcWKrdHnvckBw\iCqaYP0bYRqdmVvdHHn[4VlKHKnY3;tZolv[W62IFXHSnIh[3m2b4DsZZNucWNiZH;tZYlvKCijbXnuc{Bi[2mmczC2OFUuOTF6NjmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBmdnq7bXWgZZV1d3Cqb4PwbI9zgWyjdHnvckBjgSCGRVzGTWEwfGmvZT3y[ZNwdH[nZDDmcJVwem:vZYTyfUwhUUN3MDC9JFAvODNizszNMi=>	NV3NTGdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO\|I1OjFpPkK1NVczPDJzPD;hQi=>
Sf9	M4jTOWZ2dmO2aX;uJIF{e2G7			M2fLRWlvcGmkaYTpc44hd2ZiRVfGVkBkgXSxcHzhd41q[yCmb33hbY4hMGGvaX7vJIFkcWS\|IE[0OUB1dyBzMUi2LUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGWweont[UBifXSxcHjvd5Bpd3K7bHH0bY9vKGK7IFTFUGZKSSC2aX3lJJJme2:udnXkJIZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yMzFOwG0v	NV7MPWFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOFU2PzBpPkKzNlQ2PTdyPD;hQi=>
A549	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmfPNlQhcHK\|	M3i3WmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMD6wN{DPxE1w	MmqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OUGzOlQoRjJ\|M{mxN\|Y1RC:jPh?=
Sf9	Ml;LSpVv[3Srb36gZZN{[Xl?		NX3WOYF7OTBibXnudy=>	M{jub2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSWdHWiCtaX7hd4Uh[3m2b4DsZZNucWNiZH;tZYlvKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIV5eHKnc4Ppc44hfmWldH;yMYlv\mWldHXkJIlve2WldDDz[lkh[2WubIOgZZN{\XO\|ZXSgZZMhdGW4ZXygc4Yh[XW2b4Doc5NxcG:{eXzheIlwdiCjZoTldkAyOCCvaX7zJIJ6KESHTF\JRU91cW2nLYLld49tfmWmIH\seY9zd22ndIL5MEBKSzVyIE2gNE4xOyEQvF2u	NESxb\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2NlY3OCd-MkO5OlI3PjB:L3G+
NCI-H292	M4Ptb2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYjldHJWPzJiaILz	NFrXbHlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjl{IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnIh[W[2ZYKgO\|IhcHK\|IHL5JIx2dWmwZYPj[Y5k\SCjc4PhfUwhTUN3MDC9JFAvODNzIN88UU4>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3NUmxPUc,OjZ2NUW5NVk9N2F-
Sf9	M1vRPGZ2dmO2aX;uJIF{e2G7		MmfINUBpeg>?	NIfCS5lKdmirYnn0bY9vKG:oIHH1eI9xcG:\|cHjvdplt[XSrb36gc4YhemWlb33ibY5idnRiRVfGVkBkgXSxcHzhd41q[yCmb33hbY4hMDZ2NTD0c{AyOTh4KTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBpeiCkeTDESWxHUUFxdHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLkCzNkDPxE1w	NXuwOplZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NFc6QThpPkK0OlA4QTl6PD;hQi=>
Sf9	MYHGeY5kfGmxbjDhd5NigQ>?		NWLSXGtPOSCqch?=	MoTsTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJiY4n0c5Bt[XOvaXOg[I9u[WmwIDjhcYlvdyCjY3nkd{A3PDVidH:gNVE5PiliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nlidHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMEOyJO69VS5?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MESxNkc,OjR4M{C0NVI9N2F-
Sf9	NWjwWVlkTnWwY4Tpc44h[XO\|YYm=		Mni4NVAhdWmwcx?=	M1roTGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSWdHWiCleYTvdIxie22rYzDkc41icW5iKE[0OUB1dyBzMUi2LUApfW6tbn;3ckBwemmpaX6pJIF2fG:yaH;zdIhwenmuYYTpc44h\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCxNEBucW6\|IH\vcIxwf2WmIHL5JGFVWC2PZ1PsNkBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvODN{IN88UU4>	NGnWfZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0OFg2PCd-MkSxOFQ5PTR:L3G+
A431	NUG5NI1XTnWwY4Tpc44h[XO\|YYm=			NXHmeZk2UW6qaXLpeIlwdiCxZjDFS2ZTKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZpkhTUyLU1GsJGlEPTBiPTCwMlA{PCEQvF2u	M2jZNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{S2OlU2Lz5{MEO0OlY2PTxxYU6=
A549	MmDVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4rzO\|Q5KGi{cx?=	NFGwTVFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMESg{txONg>?	MnniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5OVYoRjJ7NEC3PVU3RC:jPh?=
B16/F10	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGfER\|k1QCCqcoO=	Mn7kRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEMU[vSlExKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA2KM7:TT6=	NX\KXGJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOFU5ODJpPkKzNlQ2QDB{PD;hQi=>
MIAPaCa	MXfGeY5kfGmxbjDhd5NigQ>?			MljqTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNTWFR[UOjIHPlcIx{KGK7IFXMTXNCNCCLQ{WwJF0hOC5yNUGg{txONg>?	NYLGXIdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4NVc2OjNpPkKwPFE4PTJ\|PD;hQi=>
A431	M3jqVGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkD4OFghcHK\|	M3rHVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMhd3[ncjDlfJBz\XO\|aX7nJGVITlJiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEW1JO69VS5?	NXTsOnlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NVQ3OTJpPkKyOFE1PjF{PD;hQi=>
Sf9	M4m3TmZ2dmO2aX;uJIF{e2G7			NUHxbWdUUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuLXzlcod1cCCJU2SteIFo\2WmIHj1cYFvKEJvUlHGJHY3ODCHIH31eIFvfCBqNEG3JJRwKDd4NjDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKEKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmPUBk\WyuczD1d4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5iTVXLNUBieyC\|dXLzeJJifGViYomgUpUueGGpZTDn[Ywu[mG\|ZXSgdIhwe3Cqb4Kgd4Nz\WWwIHHuZYx6e2m\|LDDJR\|UxKD1iMD6wOkDPxE1w	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2OUi0NUc,Ojl3NEm4OFE9N2F-
Sf9	Mn\6SpVv[3Srb36gZZN{[Xl?		MYOxNEBucW6\|	NYn1TnZ[UW6qaXLpeIlwdiCxZjDIbZM3NXSjZ3fl[EBz\WOxbXLpcoFvfCCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckApfW6tbn;3ckBwemmpaX6pJEg3PDVidH:gNVE5PiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoLUmgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzMDDtbY5{KG[xbHzve4VlKGK7IFHUVEBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFTFUGZKSS:WaX3lMXJme2:udnXkJIZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yNjFOwG0v	NXKzPXQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PTNpPkK4OFMyOzV\|PD;hQi=>
MCF7	NEmwR4tCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYi0PEBpenN?	MmHiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC3JO69VS5?	NGjLS5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2NVI4Oid-MkKzOlEzPzJ:L3G+
PC9	Mk\WRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXK2XHFsQTZiaILz	NEe4dXpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDPUBk\WyuczDh[pRmeiB7NjDodpMh[nliU4n0c5gh\3KnZX6gcYFzc2W{IHLhd4VlKG[udX;y[ZNk\W6lZTDhcoFtgXOrczygTWM2OCB;IECuNFch\|ryPLh?=	NYjFVotFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVk2OzJpPkK2OVk6PTN{PD;hQi=>
LoVo	MmHESpVv[3Srb36gZZN{[Xl?		M2npNFIhcHK\|	NYfEdGpkUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVG:YbzDj[YxteyCjZoTldkAzKGi{czDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB5NzFOwG0v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|MEm5OEc,OjN7M{C5PVQ9N2F-
HepG2	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4rETVQ5KGi{cx?=	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC4JO69VS5?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzNkWxO{c,OjF6MU[1NVc9N2F-
MCF7	NFzWWIVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVO0PEBpenN?	NGTEdZdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFgh\|ryPLh?=	M2SyflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUi4OlI1Lz5{OEm4PFYzPDxxYU6=
Sf9	NHHsT\|lHfW6ldHnvckBie3OjeR?=		Mn\WNVAhdWmwcx?=	NIjwSolKdmirYnn0bY9vKG:oIFjpd\|YufGGpZ3XkJGVITlJiKIXub45wf25ib4Lp[4lvMSCleYTvdIxie22rYzDkc41icW5iZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMh[W[2ZYKgNVAhdWmwczDmc4xtd3enZDDifUBi\GSrdHnvckBw\iCDVGCtUYdEdDJiYX7kJI1m[XO3cnXkJIFnfGW{IEGgbJIh[nlidHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLkC4JO69VS5?	NXfsb\|N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PTZpPkK5OFA4QTV4PD;hQi=>
Sf9	MV7GeY5kfGmxbjDhd5NigQ>?			NFjheGFKdmirYnn0bY9vKG:oIFjpd{03KHSjZ3fl[EBz\WOxbXLpcoFvfCCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckApPjR3IITvJFEyQDZicnXzbYR2\XNrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDj[YxteyCkeTDkbZN{d2OrYYTpc44u\W6qYX7j[YQhdGGwdHjhcoll\SCobIXvdoV{[2WwY3WgbY1ufW6xYYPzZZkwfGmvZT3y[ZNwdH[nZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjB6IN88UU4>	NXXrcYpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFk5PDFpPkK5OVQ6QDRzPD;hQi=>
MCF7	Mke1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIrhXW8zPCCqcoO=	NV7rdmZqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTCwMlA5KM7:TT6=	M{nhTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{mxN\|Y1Lz5{M{O5NVM3PDxxYU6=
BA/F3	NF7TTldHfW6ldHnvckBie3OjeR?=		MXG0PEBpenN?	NXnLZWlrUW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KFiWVDDhd5NigSxiSVO1NEA:KDBwMEi3JO69VS5?	NV\hU3d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyN\|U5PDFpPkK3NlM2QDRzPD;hQi=>
Sf9	M1rDZWZ2dmO2aX;uJIF{e2G7		M1OwdFUhdWmwcx?=	MoLnTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCJU2SteIFo\2WmIFjFVlIhMDZ5Nj3lcoQqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgOUBucW6\|IH\vcIxwf2WmIHL5JGFVWCCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiM{CgcYlveyCkeTDIWHJHKGG\|c3H5MEBKSzVyIE2gNE4xQTFizszNMi=>	MknxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOU[1PFAoRjNyMEm2OVgxRC:jPh?=
A431	NELMZVVEgXSxdH;4bYNqfHliYYPzZZk>		NVj1UYhIPzJiaILz	M1HtTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvODl4IN88UU4>	MkXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OEi3OlEoRjF7OEi4O\|YyRC:jPh?=
B16F10	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWO0PEBpenN?	Moi0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEMU\GNVAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNUDPxE1w	NITRXWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2NVI4Oid-MkKzOlEzPzJ:L3G+
MCF7	M1fScGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWrCdJE{OTJiaILz	NUDPNFNNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEGyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEh\|ryPLh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkS4Nkc,OjZ4NUK0PFI9N2F-
A549	NYTHPHNySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWG0PEBpenN?	NHnOPVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNUDPxE1w	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5MkSyNUc,OjVzN{K0NlE9N2F-
HepG2	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1[0NVQ5KGi{cx?=	NGTiVW1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEh\|ryPLh?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5MkSyNUc,OjVzN{K0NlE9N2F-
Sf9	NHPjbo1HfW6ldHnvckBie3OjeR?=			NH7xO2FKdmirYnn0bY9vKG:oIHj1cYFvKGOub37l[EBJTVJ{IHH1eI9xcG:\|cHjvdplt[XSrb36g[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|LXnu[oVkfGWmIGPmPUBk\WyuczDifUB{d2yrZD3wbIF{\SCHTFnTRUwhUUN3MDC9JFAvOTJizszNMi=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizO{c,OTl7MUS4N\|c9N2F-
HepG2	NFvMR\|JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MoixOFghcHK\|	NVnsOY9xSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOiEQvF2u	NF7RXZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGxNlU1OSd-MkKxNVI2PDF:L3G+
B16F10	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1vzZVQ5KGi{cx?=	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEJzNl[xNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	M1ruPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUi4OlI1Lz5{OEm4PFYzPDxxYU6=
HepG2	M{fYe2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{m0O\|Q5KGi{cx?=	M4riTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVIh\|ryPLh?=	NY\JfXhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NFc6QThpPkK0OlA4QTl6PD;hQi=>
HepG2	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mm[3OFghcHK\|	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGyJO69VS5?	NEm2cYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNFQyOid-MkS2N\|A1OTJ:L3G+
HepG2	NIjOTVJEgXSxdH;4bYNqfHliYYPzZZk>		NFy2RWk1QCCqcoO=	NVjPfFVJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVIh\|ryPLh?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2NEi1OEc,OjRzNES4OVQ9N2F-
HepG2	Mnj1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYCxNkBpenN?	MkLKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiBzMjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkS4Nkc,OjZ4NUK0PFI9N2F-
HepG2	NXfx[\|JoSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYK0PEBpenN?	MlG5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUW3NEc,OjN{NEW1O\|A9N2F-
HepG2	NFXFe4FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFjTWmQ1QCCqcoO=	M3\Y[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVIh\|ryPLh?=	M1;ocVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[yOlYxLz5{M{m2NlY3ODxxYU6=
U251	M3jEWmZ2dmO2aX;uJIF{e2G7			NVzX[\|B[UW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gbJVu[W5iVUK1NUBk\WyuczDifUBxcG:\|cHjveJlzd3OrbnWgSWxKW0FiYYPzZZktKEmFNUCgQUAxNjF{NEeg{txONg>?	NVzCT2x4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVA3PTJpPkK0PFkxPjV{PD;hQi=>
U251	MoOxSpVv[3Srb36gZZN{[Xl?		NV33ZYR{PjBibXnudy=>	M{[4TWlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJHZGT0[UMjDhZ5RqfmG2aX;uJIlvKGi3bXHuJHUzPTFiY3XscJMheHKndILlZZRm\CCob4KgOlAhdWmwczDmc4xtd3enZDDifUBXTUeIIHHk[Il1cW:wIHHu[EBu\WG\|dYLl[EBi\nSncjCxNEBucW6\|IHL5JGVNUVODLDDJR\|UxKD1iMD6xNlQ4KM7:TT6=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OEi2PUc,OzByOUi4Olk9N2F-
U251	NYW0XHNUTnWwY4Tpc44h[XO\|YYm=		MnLJOlAhdWmwcx?=	NXjkPXdCUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gbJVu[W5iVUK1NUBk\WyuczDjc41xd3WwZDDwdoV1emWjdHXkJIZweiB4MDDtbY4h[mWob4LlJHZGT0Zic4TpcZVt[XSrb36g[o9zKDFyIH3pcpMh[nlicHjvd5Bpd3S7cn;zbY5mKEWOSWPBJIN6fG:kbH;0JI1mfGixZDygTWM2OCB;IECuNVI1PyEQvF2u	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6MkWxPUc,OjV6OEK1NVk9N2F-
A549	MojxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2PmelQ5KGi{cx?=	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUOg{txONg>?	Ml36QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MEe5PVgoRjJ2NkC3PVk5RC:jPh?=
A549	M4nvT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUTVeHBbPDhiaILz	NFXqSphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVMh\|ryPLh?=	MlzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{C0NVIoRjJ2NkOwOFEzRC:jPh?=
A549	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		NW[4eGFoPDhiaILz	MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjF\|IN88UU4>	M1\SVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS0PFU1Lz5{NEG0OFg2PDxxYU6=
A549	M4HvUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3i3[FQ5KGi{cx?=	NH7Kb\|ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVMh\|ryPLh?=	M4ftd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[yOlYxLz5{M{m2NlY3ODxxYU6=
HCT116	M13xOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4PWSVQ5KGi{cx?=	NGTSRWNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yPCEQvF2u	NWG2ellVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
DIFI	MkPlR5l1d3SxeHnjbZR6KGG\|c3H5		MYO0JIRigXN?	NGDoTlhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFUU[LIHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvOTRizszNMi=>	MmLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
Sf9	NYLXdnVQTnWwY4Tpc44h[XO\|YYm=		NInLNIgyKGi{	MnviTY5pcWKrdHnvckBw\iCqaYP0bYRqdmVvdHHn[4VlKGi3bXHuJJJm[2:vYnnuZY51KGO7dH;wcIF{dWmlIHTvcYFqdiCxZjDISXIzKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nliRFXMSmlCN3SrbXWtdoV{d2y4ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5zNDFOwG0v	M2\kSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{[xNlczLz5{MkO2NVI4OjxxYU6=
Sf9	MYHGeY5kfGmxbjDhd5NigQ>?			NVjIZWlYUW6qaXLpeIlwdiCxZjDoeY1idiClbH;u[YQhUEWUMjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgZpkhe2:uaXStdIhie2ViRVzJV2EtKEmFNUCgQUAxNjF4IN88UU4>	M3[yflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUG0PFM2Lz5zOUmxOFg{PTxxYU6=
Sf9	M3jP[WZ2dmO2aX;uJIF{e2G7		NHLRWWsyKGi{	MXrJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEirc{\4MZRi\2enZDDISXIzKGG3dH;wbI9{eGixconsZZRqd25iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFXMTXNCNCCLQ{WwJF0hOC5zNjFOwG0v	NXHH[5dCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1PVQ5PTlpPkKwOVk1QDV7PD;hQi=>
Sf9	NFS2N5ZHfW6ldHnvckBie3OjeR?=		MYKxJIhz	NWfZRXRbUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKGi3bXHuJGhGWjJiY4n0c5Bt[XOvaXOg[I9u[WmwIDjhcYlvdyCjY3nkd{A3PzZidH:gNVI1PSliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nlidHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMU[g{txONg>?	M4KzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOwOFEzLz5{NE[zNFQyOjxxYU6=
Sf9	M1PCW2Z2dmO2aX;uJIF{e2G7			M{TFRWlvcGmkaYTpc44hd2ZiaIXtZY4hUEWUMjDjfZRweGyjc33pZ{Bld22jaX6gLIFucW6xIHHjbYR{KDZ5NjD0c{AyOjR3KTDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGK7IFTFUGZKSSC2aX3lJJJme2:udnXkJIZtfW:{b33leJJ6NCCLQ{WwJF0hOC5zNjFOwG0v	NIPaXlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K0OVgxOid-MkOyOFU5ODJ:L3G+
B16F10	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MkXqNVIhcHK\|	NVfXSGJ7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgNVIhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTdizszNMi=>	M3LxT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyOFgzLz5{Nk[1NlQ5OjxxYU6=
HeLa	NIDqOW5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFj4XG8yOiCqcoO=	M1fseGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiBzMjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6yJO69VS5?	M{fBZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyOFgzLz5{Nk[1NlQ5OjxxYU6=
Sf9	M4W1TGZ2dmO2aX;uJIF{e2G7			M1PMS2lvcGmkaYTpc44hd2ZiaHnzeIllcW6nLYTh[4dm\CC{ZXPvcYJqdmGwdDDISXIzKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iZX76fY1mKGG3dH;wbI9{eGixconsZZRqd25iYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LvcYV1enluIFnDOVAhRSByLkKg{txONg>?	M2G4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOFIyLz5{NUG3NlQzOTxxYU6=
A16-F10	NHn0V\|VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWm0Z3ZiPDhiaILz	NVnySI9SSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNVYuTjFyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJizszNMi=>	MnvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NEW1O\|AoRjJ\|MkS1OVcxRC:jPh?=
MDA-MB-468	NInve3FEgXSxdH;4bYNqfHliYYPzZZk>			NXPkTHV[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfHKrcHzlJI5m\2G2aY\lJG1FSS2PQj20Olgh[2WubIOsJGlEPTBiPTCwMlI{PTJizszNMi=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh7ME[1Nkc,OjR6OUC2OVI9N2F-
CAL27	M3\NXGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mm\iOEBl[Xm\|	MlXYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2FNOjdiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gNE4zOzlizszNMi=>	NVnRPIxvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
Sf9	MnLJSpVv[3Srb36gZZN{[Xl?		NGfEbnU2KG2rboO=	Mn7MTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIILlZ49u[mmwYX70JIh2dWGwIG\FS2ZTKCh5OEmt[Y5lMSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{BxemWrbnP1ZoF1\WRiZn;yJFUhdWmwczDmc4xtd3enZDDifUBCXFBiYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgTHRTTiCjc4PhfUwhUUN3MDC9JFAvOjVizszNMi=>	NGTSPY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC5OlU5OCd-M{CwPVY2QDB:L3G+
A549	M{LRZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmnwOFghcHK\|	NEPVZlZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYnHzZYwh[2WubDDndo94fGhiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMkeg{txONg>?	M4nhOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{[zNVQ5Lz5{MUe2N\|E1QDxxYU6=
T24 NIH	MmjRSpVv[3Srb36gZZN{[Xl?			NELt[mNKdmirYnn0bY9vKG:oIHzp[4Fv\CC\|dHnteYxifGWmIHXyZmIzKGG3dH;wbI9{eGixconsZZRqd25iaX6gWFI1KE6LSDDj[YxteyxiSVO1NEA:KDBwMkm5JO69VS5?	Mn[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2OECyPFQoRjF4NEiwNlg1RC:jPh?=
GXF251L	NITwdZdEgXSxdH;4bYNqfHliYYPzZZk>		M1fGc\|Qh\GG7cx?=	MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDHXGYzPTGOIHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvOzZ7IN88UU4>	Mor5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
A431	NX\tb5VmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mlj3O\|IhcHK\|	NETLb5BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0N\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuOFA6KM7:TT6=	M1v4XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUizO\|QzLz5{NEG4N\|c1OjxxYU6=
MDA-MB-231	MYnDfZRwfG:6aXPpeJkh[XO\|YYm=			M{nxbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJRzcXCuZTDu[YdifGm4ZTDNSGEuVUJvMkOxJINmdGy\|LDDJR\|UxKD1iMD60N\|g2KM7:TT6=	MlzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
A431	Mm\GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4W2VFczKGi{cx?=	MknhS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVQ{OSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjR5IN88UU4>	M2S0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUizO\|Q2Lz5zN{m4N\|c1PTxxYU6=
BA/F3	NVrKWW1JT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{exfFk3KGi{cx?=	M1LCWWdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBF\WxzIH31eIFvfCCjZoTldkA6PiCqcoOgZpkh[2WubDD0bZRmei2pbH:gZZN{[XluIFfJOVAhRSByLkWg{txONg>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ{MkezN{c,OjB{MkK3N\|M9N2F-
BA/F3	NXH0e5JXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NX\PcYluQTZiaILz	NFrid\|NIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTGWuMzDteZRidnRiYX\0[ZIhQTZiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDHTVUxKD1iMD61JO69VS5?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ{MkezN{c,OjB{MkK3N\|M9N2F-
BA/F3	NGDDXIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYXJV4RNQTZiaILz	NHTIb\|JIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTGWuNTDteZRidnRiYX\0[ZIhQTZiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDHTVUxKD1iMD61JO69VS5?	M3LBPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkKyO\|M{Lz5{MEKyNlc{OzxxYU6=
BA/F3	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2nkT\|k3KGi{cx?=	MWnHdo94fGhiaX7obYJqfGmxbjDv[kBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgUFg2QFJibYX0ZY51KGGodHXyJFk3KGi{czDifUBk\WyuIITpeIVzNWeubzDhd5NigSxiR1m1NEA:KDBwNTFOwG0v	NGr2cnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEKyNlc{Oyd-MkCyNlI4OzN:L3G+
Huh7.5	MW\BcpRqfmm{YXygZZN{[Xl?		MYq3NkBpenN?	M2DCfGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhmeGG2aYTpd{BEKH[rcoXzJGo3N0qISDDpcoZm[3SnZDDpckBpfW2jbjDIeYg4NjViY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckBu\WG\|dYLl[EBi\nSncjC3NkBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOC53IN88UU4>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh{MkezPUc,OjV6MkK3N\|k9N2F-
Huh7.5	MmH4RY51cX[rcnHsJIF{e2G7		NX;2UpJ7PzJiaILz	NVzmVnYzSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMhUjZxSl\IJIVt\WO2cn;wc5JifGWmIHnuJIh2dWGwIFj1bFcvPSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIlvfHKjY3XscJVt[XJiaX7m[YN1cX[rdImg[JJ2\yC2cnXheIVlKGW4ZYL5JFI1KGi{czDmc5IhPzJiaILzJI1m[XO3cnXkJFczKGi{czDwc5N1KGWuZXP0do9xd3KjdHnvckBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTBiPTCwMlUh\|ryPLh?=	NXP0T2poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NlI4OzlpPkK1PFIzPzN7PD;hQi=>
Huh7.5	MlLsRY51cX[rcnHsJIF{e2G7		MW[3NkBpenN?	M1;RSWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhmeGG2aYTpd{BEKH[rcoXzJGo3N0qISDDpcoZm[3SnZDDpckBpfW2jbjDIeYg4NjViY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBmgHS{YXPlcIx2dGG{IHnu[oVkfGm4aYT5JIRzfWdidILlZZRm\CCndnXyfUAzPCCqcoOg[o9zKDd{IHjyd{Bu\WG\|dYLl[EBi\nSncjC3NkBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOC53IN88UU4>	M{HqWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEKyO\|M6Lz5{NUiyNlc{QTxxYU6=
HEK293	NVXscYhmTnWwY4Tpc44h[XO\|YYm=		NET6TIg2KG2rboO=	NGHBeoFKdmirYnn0bY9vKG:oIHj1cYFvKGyrdnXyJG9CXFB{QkGg[ZhxemW\|c3XkJIlvKEiHS{K5N{BHdHBvSX6gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFt\|SG3FN3MhfXC2YXvlJIlv[3WkYYTl[EBnd3JiNTDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEurIE2gNE42OyEQvF2u	NFryT5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
HEK293	NHrrcmlHfW6ldHnvckBie3OjeR?=		MUG1JI1qdnN?	M2riSmlvcGmkaYTpc44hd2ZiaIXtZY4hdGm4ZYKgU2FVWDKEMTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJGZteC2LbjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hYzOKXVWzV{B2eHSja3WgbY5kfWKjdHXkJIZweiB3IH3pcpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvPTVizszNMi=>	NFXiV\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
A431	NFftcmdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWfWdIJCPzJiaILz	Ml\vRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEOxJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlU3KM7:TT6=	M3H2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[1PVY6Lz5{NEW2OVk3QTxxYU6=
MDA-MB-435	NFz2XJlEgXSxdH;4bYNqfHliYYPzZZk>			MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy\|LDDJR\|UxKD1iMD62NlIyKM7:TT6=	NHjsUpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi5NFY2Oid-MkS4PVA3PTJ:L3G+
LXFA 629L	NHq1cmxEgXSxdH;4bYNqfHliYYPzZZk>		NIHMXVU1KGSjeYO=	MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZCKDZ{OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC54NjFOwG0v	M4jJU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
A549	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		MVyyOEBpenN?	MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlc{KM7:TT6=	NV\DdoNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwNlg2OzRpPkK5NFI5PTN2PD;hQi=>
A431	Mn;TR5l1d3SxeHnjbZR6KGG\|c3H5		MVm3NkBpenN?	MlHVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuO\|Uh\|ryPLh?=	M3L1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
A431	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1\pW\|czKGi{cx?=	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF2M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFSz24JIF{e2G7LDDJR\|UxKD1iMD64OFQh\|ryPLh?=	NInRbHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS4O\|kyPyd-Mk[0PFc6OTd:L3G+
A431	NGTPWpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUj4PYxCPzJiaILz	MlyzS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVQ{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUTVyIE2gNE46OTVizszNMi=>	M1vhU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[5OFY2Lz5zOUm2PVQ3PTxxYU6=
Calu3	Mn;JR5l1d3SxeHnjbZR6KGG\|c3H5		NIjibpc4OiCqcoO=	MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYx2OyClZXzsd{BmgHC{ZYPzbY5oKEiHUkKgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuPVMh\|ryPLh?=	NIntPFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVEzOyd-MkS0NVEyOjN:L3G+
DU145	MmC5R5l1d3SxeHnjbZR6KGG\|c3H5		M4LU[VQh\GG7cx?=	NF3ufFdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjl4NjFOwG0v	MoTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
NCI-H2122	M2jNbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			M12z[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOTJ{IHPlcIx{NCCLQ{WwJF0hOSEQvF2u	NW\tT2hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
NCI-H292	NHrJeJFEgXSxdH;4bYNqfHliYYPzZZk>		M4fueVczKGi{cx?=	NITPcGREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEK5NkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMTFOwG0v	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzNUi1Okc,OjV{MUW4OVY9N2F-
A431	NEjHS\|VHfW6ldHnvckBie3OjeR?=		NFjkbpMyOCCvaX7z	MVPJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZYZ1\XJiMUCgcYlveyCkeTDGUGlUSSxiSVO1NEA:KDFwMjFOwG0v	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyM{ewNEc,OjB2MEO3NFA9N2F-
A431	MVTGeY5kfGmxbjDhd5NigQ>?			MlLLTY5pcWKrdHnvckBw\iCHR1\SJIV5eHKnc4Pl[EBqdiCqdX3hckBCPDNzIHPlcIx{NCCLQ{WwJF0hOS5{IN88UU4>	MnvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NUiwO\|IoRjJyNUW4NFczRC:jPh?=
A431	M2jFTWZ2dmO2aX;uJIF{e2G7		MnLEOlAhdWmwcx?=	M3fvb2lvcGmkaYTpc44hd2ZiRVfGVkB1gXKxc3nu[UBscW6jc3WgZYN1cX[rdImgbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iQUSzNUBk\WyuczDh[pRmeiB4MDDtbY5{KGK7IFXMTXNCNCCLQ{WwJF0hOS5{IN88UU4>	M2\UdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC0O\|QyLz5{MkKwOFc1OTxxYU6=
A431	MkjsSpVv[3Srb36gZZN{[Xl?		M4Px[VYxKG2rboO=	NFvuXnRKdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEF2M{GgZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjDwdoV1emWjdHXkJIZweiB4MDDtbY5{KHC{aX;yJJRwKEWJRjDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiBzMDDtbY5{KGK7IIDoc5NxcG:2eYLvd4lv\SCHTFnTRUBkgXSxYnzveEBidmGueYPpd{whUUN3MDC9JFEvOiEQvF2u	MkfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|N{WwPVAoRjJ\|M{e1NFkxRC:jPh?=
A431	NX7yVXQ4TnWwY4Tpc44h[XO\|YYm=		NV;UNoh5PjBibXnudy=>	NHvBZnRKdmirYnn0bY9vKG:oIFXHSnIhcW5iaIXtZY4hSTR\|MTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIIT5do9{cW6nIIDoc5NxcG:{eXzheIlwdiCrbnP1ZoF1\WRiZn;yJFYxKG2rboOgdJJqd3JidH:gSWdHNWGldHn2ZZRqd25ibXXhd5Vz\WRiMUCgcYlveyCkeTDFUGlUSSxiSVO1NEA:KDFwMjFOwG0v	NWjzfIt[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0N\|QyOzlpPkKzOFM1OTN7PD;hQi=>
A431	NYnFWZIzTnWwY4Tpc44h[XO\|YYm=		MVW2NEBucW6\|	NXHGSIF6UW6qaXLpeIlwdiCxZjDFS2ZTKGmwIHj1cYFvKEF2M{GgZ4VtdHNicILleJJm[XSnZDDmc5IhPjBibXnud{Bu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFXMTXNCNCCLQ{WwJF0hOS5{IN88UU4>	NIXY[oE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkezPVA6OCd-MkK3N\|kxQTB:L3G+
H9	NV2zPJFZSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2rlTlczKGi{cx?=	NILEdFRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMT6zJO69VS5?	NUjqNVdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVk2OzJpPkK2OVk6PTN{PD;hQi=>
PC9	M4Owe2Z2dmO2aX;uJIF{e2G7		MVWyOEBpenN?	NUjYeJF2UW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSzliY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczygTWM2OCB;IEGuN\|Yh\|ryPLh?=	NYnNPY5sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5PFAzOThpPkKyPVgxOjF6PD;hQi=>
SK-BR-3	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLVLSMVMh[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwJF0hOS53NjFOwG0v	NVfWZ4g{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
LXFA 289L	M4DzR2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NIHWW4g1KGSjeYO=	MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZCKDJ6OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOS55ODFOwG0v	Ml\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
SCC15	NX\xSIxjSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NHrtcXZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPDR\|E2KGOnbHzzMEBKSzVyIE2gNU46PCEQvF2u	NH;FUXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
Jurkat	M2\Pc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1OwV\|I1KGi{cx?=	NFXrPYZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBLfXKtYYSgZ4VtdHNiYX\0[ZIhOjRiaILzMEBKSzVyIE2gNkDPxE1w	Mn:2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzN{i3NlIoRjF5MUe4O\|IzRC:jPh?=
erythroleukemia cell	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmTTNlQhcHK\|	MWnHdo94fGhiaX7obYJqfGmxbjDv[kBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPzbY5oKGi3bXHuJIVzgXSqcn;s[ZVs\W2rYTDj[YxteyCjZoTldkAzPCCqcoOsJGlEPTBiPTCyJO69VS5?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF5OEeyNkc,OTdzN{i3NlI9N2F-
erythroleukemia cell	NVf2NHB{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkPKNlQhcHK\|	NXz3RYdbT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4Uh\XK7dHjyc4xmfWunbXnhJINmdGy\|IHHmeIVzKDJ2IHjyd{whUUN3MDC9JFIh\|ryPLh?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF5OEeyNkc,OTdzN{i3NlI9N2F-
NCI-H1993	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=		M3\pdVQ5KGi{cx?=	NHP5bZNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEG5PVMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuNFQ{KM7:TT6=	MmnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
HT-29	NE\3SJVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1vxXVczKGi{cx?=	NVezNW9ESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckB2dmSncjDuc5Jud3irYTDjc45lcXSrb37zJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCyMlk5KM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4OEC0OEc,OjV2NkiwOFQ9N2F-
PANC1	M2HCeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUPzN2hYPzJiaILz	NIDSd5RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBRSU6FMTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONLUigZZN{[XluIFnDOVAhRSB\|LkGg{txONg>?	MljyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NEe2PVAoRjJ4NUS3OlkxRC:jPh?=
SCC25	M1TGZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOFQ{K1JINmdGy\|LDDJR\|UxKD1iMz6zOEDPxE1w	M{S0Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
NCI-H358	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{i4cFQ5KGi{cx?=	NEe2TolCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzV6IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliY3PrPEBie3OjeTygTWM2OCB;IEOuPVEh\|ryPLh?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ\|NEi4O{c,Ojd{M{S4PFc9N2F-
COS7	NYDkdWVlTnWwY4Tpc44h[XO\|YYm=			MVfJcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJiVk[xO2YhdXW2YX70JIV5eHKnc4Pl[EBqdiCFT2O3JINmdGy\|LDDJR\|UxKD1iNDFOwG0v	M{PlOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUe4O\|IzLz5zN{G3PFczOjxxYU6=
L3.6PL	NHmyUopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MY[3NkBpenN?	MlXGS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUFMvPlCOIHPlcIx{KGGodHXyJFczKGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDRizszNMi=>	NFq2e5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW0O\|Y6OCd-Mk[1OFc3QTB:L3G+
HT-29	NYKxRm1ISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MkLTO\|IhcHK\|	NWnRdG5RSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckB2dmSncjDofZBwgGmjIHPvcoRqfGmxboOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IESuN\|ch\|ryPLh?=	NIDMVYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2PFA1PCd-MkW0OlgxPDR:L3G+
OVCAR3	NVzLfYxPSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2T1clczKGi{cx?=	M1HkfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT2\DRXI{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gOE43KM7:TT6=	NFriWYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
Calu3	M2[3dGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NU[yVpFLPzJiaILz	NV\nNllESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDZYx2OyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyJIJtfWViYYPzZZktKEmFNUCgQUA1NjdizszNMi=>	NXGzSYhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVk2OzJpPkK2OVk6PTN{PD;hQi=>
hematopoietic progenitor cell	NE\US3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1jVU2dzd3e2aDDpcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5NqdmdiaHXtZZRweG:rZYTpZ{Bxem:pZX7peI9zKGOnbHzzJIl{d2yjdHXkJIZzd21icH;sfYN6fGinbXnhJJZmemFicHH0bYVvfCCkeTDjc4xwdnliZn;ycYlv\yCjc4PhfUwhUUN3MDC9JFUh\|ryPLh?=	MoHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzN{i3NlIoRjF5MUe4O\|IzRC:jPh?=
KB	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{DlRlQ5KGi{cx?=	NH3IfXhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCJINmdGy\|IHX4dJJme3OrbnegSWdHWiCjbnSgV5JkKGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA2KM7:TT6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF6OE[yNEc,OjZzOEi2NlA9N2F-
N87	M3XEbmZ2dmO2aX;uJIF{e2G7			MXnJcohq[mm2aX;uJI9nKEW{YlKyJIlvfHKjY3XscJVt[XJicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKE56NzDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDVwMjFOwG0v	MkjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|NE[2OVUoRjJyM{S2OlU2RC:jPh?=
NCI-H1975	NYLh[3JOS3m2b4TvfIlkcXS7IHHzd4F6		MYS3NkBpenN?	NFixc4NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEG5O\|Uh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIFy4OVhTN1R5OUDNJI12fGGwdDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNT61NUDPxE1w	NIfaeo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVEzOyd-MkS0NVEyOjN:L3G+
MRC5	Mn;tRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYG3NkBpenN?	MknlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPUlO1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iNT64JO69VS5?	NVvJNZlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVk2OzJpPkK2OVk6PTN{PD;hQi=>
HepG2	NEPTelJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NF3aXWc1QCCqcoO=	M3PFcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuPEDPxE1w	M2rkblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEm2O\|A5Lz5{Nki5OlcxQDxxYU6=
NCI-H358	MkXRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NH;UfnNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzV6IHPlcIx{KGGodHXyJIhzeyCkeTDBWHAh[2:wdHXueEBie3OjeTygTWM2OCB;IE[g{txONg>?	M4LXblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
A549	M1zBWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			Mn\VRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJJZq[WKuZTDj[YxteyCjZoTldkA1QCCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDZwMk[g{txONg>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5OUOxOEc,OjZ6N{mzNVQ9N2F-
LNCAP	MXrDfZRwfG:6aXPpeJkh[XO\|YYm=		MmCwOEBl[Xm\|	MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTC2MlY{KM7:TT6=	NUS4PHZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
MIAPaCa	MkXESpVv[3Srb36gZZN{[Xl?			NFnmO5hKdmirYnn0bY9vKG:oIFXSRoIzKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOUUGSYVPhJINmdGy\|IHL5JGVNUVODLDDJR\|UxKD1iNj63N{DPxE1w	MkjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6MUe1NlMoRjJyOEG3OVI{RC:jPh?=
NCI-H358	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M3fMU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{PThiY3XscJMh[XO\|ZYPz[YQh[XNidnnhZoxmKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gOk45PSEQvF2u	NXTxXFFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4O\|k{OTRpPkK2PFc6OzF2PD;hQi=>
NCI-H1975	M{G4eGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUm3NkBpenN?	NVHnWJhmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNJI12fGGwdDDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNj65JO69VS5?	NGO5fVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4N\|c1Oid-MkSxPFM4PDJ:L3G+
NCI-H1975	M{e3dmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmXnO\|IhcHK\|	M2Cyc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[4VncXSrbnniMZJme2m\|dHHueEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEeuNFYh\|ryPLh?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4NUm2PUc,OjR3NkW5Olk9N2F-
A549	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=		M3myVVQ5KGi{cx?=	M3zkZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFcvODl7IN88UU4>	NIfxUYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
A549	M37XSGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXnHXFFDPDhiaILz	Mne2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgZ4NsQCCjc4PhfUwhUUN3MDC9JFcvOzVizszNMi=>	NHTG[\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{KzOFg5Pyd-MkeyN\|Q5QDd:L3G+
NCI-H1975	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		MVG0PEBpenN?	NWfzZZM6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC3MlQ6QCEQvF2u	NF21V4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
HCC827	M{e1N2FvfGmycn;sbYZmemG2aY\lJIF{e2G7			Mo[yRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O4Nlch[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwJF0hPy53IN88UU4>	M{DZcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
A549	M{OxZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4j0SVczKGi{cx?=	M4TSZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjD1coRmeiCwb4Ltc5hq[SClb37kbZRqd26\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB5LkW5JO69VS5?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4OEC0OEc,OjV2NkiwOFQ9N2F-
BxPC3	M1SyUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NGfWUVRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFL4VGM{KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NEA:KDdwNjFOwG0v	NFi5U2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
NCI-H1975	NGW5fmlHfW6ldHnvckBie3OjeR?=		NETvTpQzKGi{cx?=	NHT2XpdKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFk4OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDdwNjFOwG0v	NILQRpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mzNFk6PCd-MkO5N\|A6QTR:L3G+
PCI35	NIHtVIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mln0O\|IhcHK\|	MkfIS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGNKOzViY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNEUy16IHHzd4F6NCCLQ{WwJF0hPy55IN88UU4>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV2N{[5NEc,OjZ3NEe2PVA9N2F-
WM266.4	Mm\nRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3HhW\|I1KGi{cx?=	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFePMk[2MlQh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEiuNFkh\|ryPLh?=	NUjIO\|RRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5PFU6PTdpPkKyPVg2QTV5PD;hQi=>
WM266.4	M1K1[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVLJbWtwOjRiaILz	MX\Hdo94fGhiaX7obYJqfGmxbjDpckBpfW2jbjDXUVI3Pi52IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRicnXkeYN1cW:wIHHzd4F6NCCJSUWwJF0hQC5zMjFOwG0v	NFnpU2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm4OVk3Oid-MkK5PFU6PjJ:L3G+
WM266.4	NVn2dpBNSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUjQdFBiOjRiaILz	Ml71RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCZTUK2Ok41KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTC4MlE1KM7:TT6=	NXrVUoFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyN\|g5PDFpPkK3NlM5QDRzPD;hQi=>
H460	NVKwdJlLSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEh2NkCgZ4VtdHNiYX\0[ZIhcHK\|IHL5JGFVWCClb370[Y51KGG\|c3H5MEBKSzVyIE2gPE4zKM7:TT6=	MlL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
OVXF 899L	NWrCTXFIS3m2b4TvfIlkcXS7IHHzd4F6		MUi0JIRigXN?	NWHVNGJPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[[RjC4PVlNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEiuO\|ch\|ryPLh?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
MCF7	M1P1NWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MlKzNlQhcHK\|	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDhwOUeg{txONg>?	NGDKTpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm4OVk2Pyd-MkK5PFU6PTd:L3G+
NCI-H1975	NIDLOohHfW6ldHnvckBie3OjeR?=		M2jRclIhcHK\|	MkLUTY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUL2S3PVBOKGSxdXLs[UBufXSjboSgZZV1d3Cqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgZYZ1\XJiMjDodpMh[nlic3Hu[Jdq[2hiRVzJV2EtKEmFNUCgQUA6KM7:TT6=	NHP4WFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
H1975	MX3GeY5kfGmxbjDhd5NigQ>?		NFrKNIczKGi{cx?=	MnzPTY5pcWKrdHnvckBw\iCHR1\SJHQ4QTCPL1y4OVhTKGSxdXLs[UBufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFixPVc2KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgSWdHKHO2aX31cIF1cW:wIH\vdkAyOCCvaX7zJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gPU4xODNizszNMi=>	M{C1V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mki3O\|MxLz5{OEK4O\|c{ODxxYU6=
A549	MmiyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVK5OGVTPzJiaILz	NF70d25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36geY5l\XJiaInwc5hq[SClb37kbZRqd26\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB7LkGg{txONg>?	MnnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkiwOFQoRjJ3NE[4NFQ1RC:jPh?=
H460	M{TXcmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoC4O\|IhcHK\|	MkDzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gPU42KM7:TT6=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzNUi1Okc,OjV{MUW4OVY9N2F-
PC9-DRH	MVrGeY5kfGmxbjDhd5NigQ>?		NV;xNGc{OiCqcoO=	NVXn[o9DUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbHX0bY9vN1R5OUDNJI12fGGwdDDheZRweGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQS2GUligZ4VtdHNiYX\0[ZIhOiCqcoOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTC5Mlch\|ryPLh?=	M2\yZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
PC9-DRH	NFHVXIVHfW6ldHnvckBie3OjeR?=		MlHJNkBpenN?	MmrDTY5pcWKrdHnvckBw\iCHR1\SJHQ4QTCPL3X4c44hOTliZHXs[ZRqd25ibYX0ZY51KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSzlvRGLIJINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nliRVfGJJN1cW23bHH0bY9vKG[xcjCxNEBucW6\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iOT63N\|Yh\|ryPLh?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6N{ezNEc,Ojh{OEe3N\|A9N2F-
U937	M13qXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NY\tdZRwPzJiaILz	NFvhdJRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW5N\|ch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncjDicJVmKGG\|c3H5MEBKSzVyIE2gPU46KM7:TT6=	M2LBW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm5OVMzLz5{NkW5PVU{OjxxYU6=
PAXF 546L	M4XGSGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MXO0JIRigXN?	NFvnWFdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSViIIEW0Omwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMUCg{txONg>?	NXfObJR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
RXF 486L	M1LSeGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmX5OEBl[Xm\|	NWHLZYt[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWliIIES4Omwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMUCg{txONg>?	NEDrT2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
CAL27	NH;2WJZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			M{D5fWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1HMNlch[2WubIOsJGlEPTBiPTCxNE4yPSEQvF2u	NXTMSGI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
SKHEP1	Mn3aRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			Mn;SRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVS1jFVFEh[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwJF0hOTBwM{eg{txONg>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
MDA-MB-468	NIHpTo9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01PjhiY3XscJMtKEmFNUCgQUAyOS52IN88UU4>	NHS5ZWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SF539	NHPpU5pHfW6ldHnvckBie3OjeR?=		M4WzWFYxKG2rboO=	NXvRdZo3UW6qaXLpeIlwdiCxZjDQSGdHNUKELXnu[JVk\WRiUFTHSnIh[mW2YTDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iU1[1N\|kh[2WubIOgc5ZmemW6cILld5NqdmdiUFTHSnIh[mW2YTDwdoV1emWjdHXkJIZweiB4MDDtbY5{KHC{aX;yJJRwKFCGR1[tRmIh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNVAhdWmwczDifUBxcG:\|cHjveJlzd3OrbnWgSWxKW0FiY4n0c4Jtd3RiYX7hcJl{cXNuIFnDOVAhRSBzMj6yJO69VS5?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5NUC5NEc,OjN\|N{WwPVA9N2F-
SF539	MYjGeY5kfGmxbjDhd5NigQ>?		MVi2NEBucW6\|	NHS4THRKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTDpckBpfW2jbjDTSlU{QSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHBFT0[ULVLCMYlv\HWlZXSgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhPjBibXnud{BxemmxcjD0c{BGT0ZvYXP0bZZifGmxbjDt[YF{fXKnZDCxNEBucW6\|IHL5JGVNUVODLDDJR\|UxKD1iMUKuNkDPxE1w	Mn2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2M{SxN\|koRjJ\|NEO0NVM6RC:jPh?=
SF539	M2POPWZ2dmO2aX;uJIF{e2G7		MoHqOlAhdWmwcx?=	NUO0eYhTUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgbY4hcHWvYX6gV2Y2OzliY3XscJMheHKndILlZZRm\CCob4KgOlAhdWmwczDt[YF{fXKnZDDh[pRmeiBzIHjyJIJ6KEWOSWPBMEBKSzVyIE2gNVIvOiEQvF2u	NGW1RW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkezPVA6OCd-MkK3N\|kxQTB:L3G+
A498	NHLSdZBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{HSTFQ5KGi{cx?=	Mon6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEm4JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzMj61JO69VS5?	M3TRcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEW3NFQzLz5{OUC1O\|A1OjxxYU6=
NCI-H661	NHrETlFEgXSxdH;4bYNqfHliYYPzZZk>		NVfDfZJ2PCC2bzC1JIRigXN?	MlfwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh4NkGgZ4VtdHNiYX\0[ZIhPCC2bzC1JIRigXNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVIvPzFizszNMi=>	NGrMOIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES2OlU2PSd-MkC0OlY2PTV:L3G+
BT474	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmnkO\|IhcHK\|	M1r4SWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS0O\|Qh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncjDicJVmKGG\|c3H5MEBKSzVyIE2gNVMh\|ryPLh?=	MoLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3OUm1N\|IoRjJ4NUm5OVMzRC:jPh?=
BXF T24	MmrCR5l1d3SxeHnjbZR6KGG\|c3H5		MlzvOEBl[Xm\|	MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCXGYhXDJ2IHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFE{NjlizszNMi=>	M3m5UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
CXF 269L	NIjZOnNEgXSxdH;4bYNqfHliYYPzZZk>		NIrxco81KGSjeYO=	MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDXGYhOjZ7TDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAyPiEQvF2u	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
HEK293	NWXwfodzTnWwY4Tpc44h[XO\|YYm=		NUDaPWZZOiCvaX7z	NWfpdY9EUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2SxJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5idYD0ZYtmKG:oIFHTVEsh[W[2ZYKgNkBucW6\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFE3NjJizszNMi=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ\|MEm4OUc,Ojh{M{C5PFU9N2F-
PC3M	NIHzU4hEgXSxdH;4bYNqfHliYYPzZZk>		NXniU2ZzPCCmYYnz	NWHEfnY6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|TTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAyPy5{IN88UU4>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
A549	MVjBcpRq[2GwY3XyJIF{e2G7		M130eFk3KGi{cx?=	NU\B[IZOSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzNz6zNkDPxE1w	MnfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEm4OFEoRjJ7NUS5PFQyRC:jPh?=
LXFL 529L	M4jhcGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mnv5OEBl[Xm\|	M{DocWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkxiNUK5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSBzNz60JO69VS5?	M1\D[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
FADU	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MnjwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCIQVTVJINmdGy\|LDDJR\|UxKD1iMUig{txONg>?	NXHJdZJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVk2OzJpPkK2OVk6PTN{PD;hQi=>
LNCAP	NYPjRXRUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MmrsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOTlPBVEBk\WyuczygTWM2OCB;IEG4MlM2KM7:TT6=	M{i2TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
LO2	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=		NIW5SI81QCCqcoO=	NEPpXnBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVzJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE5NjVizszNMi=>	NYi2T29PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PVY4ODhpPkK2PFk3PzB6PD;hQi=>
MEXF 276L	NGewdZlEgXSxdH;4bYNqfHliYYPzZZk>		NGLOOpQ1KGSjeYO=	MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXhHKDJ5NlygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOThwNjFOwG0v	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
DU145	NY\ZZXc6S3m2b4TvfIlkcXS7IHHzd4F6		NVzKO3J4PCC2bzC1JIRigXN?	NWDYcnZLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPCC2bzC1JIRigXNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVkvPCEQvF2u	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR4NkW1OUc,OjB2Nk[1OVU9N2F-
MCF7	MnHSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEjETlE1QCCqcoO=	M37JfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkCg{txONg>?	M33SRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMES3OFExLz5\|MEC0O\|QyODxxYU6=
Saos2	MkHrR5l1d3SxeHnjbZR6KGG\|c3H5		NVrSR2JxPCCmYYnz	NX24do5kS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW2Gxc{KgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOjFizszNMi=>	MmizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
HEK293	MoWySpVv[3Srb36gZZN{[Xl?			NH[5UWVKdmirYnn0bY9vKG:oIHj1cYFvKGyrdnXyJG9CXFBzQkGg[ZhxemW\|c3XkJIlvKEiHS{K5N{BHdHBvSX6gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEVzNz3i[ZRiTyC3cIThb4Uh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFIyKM7:TT6=	NWPnNmY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFExPjhpPkKyOVQyODZ6PD;hQi=>
HEK293	MVrGeY5kfGmxbjDhd5NigQ>?			MU\Jcohq[mm2aX;uJI9nKGi3bXHuJIxqfmW{IF;BWHAySjFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGUyPy2kZYThS{B2eHSja3WgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygT4khRSB{MTFOwG0v	NILMR3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
A549	M1u3emFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHj3Omw4OiCqcoO=	M2f6NWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkGuN{DPxE1w	NInKZpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi4OlUxQSd-Mki4PFY2ODl:L3G+
H460/Vbl	M3HJc2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M1jnNVczKGi{cx?=	NYnIOGtUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MD;WZowh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEKxMlUh\|ryPLh?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzNUi1Okc,OjV{MUW4OVY9N2F-
UXF 1138L	M4jIc2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MUK0JIRigXN?	MkP5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWXhHKDFzM{jMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDJ2LkWg{txONg>?	NH:yTJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
MAXF 401NL	M{XQWmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUXUUlVyPCCmYYnz	NVnnb2hMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUG[RjC0NFFPVCClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCyOUDPxE1w	NIjVc2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
HepG2	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlLqOFghcHK\|	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{NTFOwG0v	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB2N{SxNEc,OzByNEe0NVA9N2F-
HepG2	NEL2WmtEgXSxdH;4bYNqfHliYYPzZZk>		M2TrbFI1KGi{cx?=	NYOxU5FsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHK7LDDJR\|UxKD1iMkWg{txONg>?	M2\KeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEi3NVI4Lz5{OES4O\|EzPzxxYU6=
HuH7	MoHaRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1X5XFQ5KGi{cx?=	M4jWO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkWg{txONg>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB3N{C0Nkc,OjlyNUewOFI9N2F-
A498	NWfyeldTSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFjBZYs1QCCqcoO=	NYHDSY5lSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhcoQhW3KlIHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB{NT62JO69VS5?	NGf3[Wk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG4PFYzOCd-Mk[xPFg3OjB:L3G+
MEXF 1341L	NV3NcWU2S3m2b4TvfIlkcXS7IHHzd4F6		NVvrRXMzPCCmYYnz	NEjpW\|FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTViIIEGzOFFNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEOwMlEh\|ryPLh?=	NFXpSVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
MDA-MB-231	M4\WPGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVHld4tbPzJiaILz	NYTRZ4o{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDNyLkGyJO69VS5?	NHrRT4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyN\|M5Oyd-Mki5NlM{QDN:L3G+
PXF 1752L	NWXtboVXS3m2b4TvfIlkcXS7IHHzd4F6		NYnKO2FHPCCmYYnz	MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQXGYhOTd3MlygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOzFwNjFOwG0v	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
A549	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		NXTWWnJlPCC2bzC1JIRigXN?	M{nWZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOEB1dyB3IHThfZMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iM{OuNFMh\|ryPLh?=	M2naclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
MDA-MB-231	Ml21RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mm\5OFghcHK\|	MoLXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFM{NjR4IN88UU4>	MlvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7MkOzPFMoRjJ6OUKzN\|g{RC:jPh?=
MDA231	NFPQXXJEgXSxdH;4bYNqfHliYYPzZZk>		MVu0JIRigXN?	M2jpVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSTJ\|MTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUA{PC53IN88UU4>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
LXFL 1121L	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		MkflOEBl[Xm\|	NUWzdm1rS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiITDCxNVIyVCClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCzOE43KM7:TT6=	MnvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
PXF 698L	NFvRVJNEgXSxdH;4bYNqfHliYYPzZZk>		Mm\qOEBl[Xm\|	Mkj3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVHhHKDZ7OFygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOzZwNDFOwG0v	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
PC3	NGf1dIZEgXSxdH;4bYNqfHliYYPzZZk>		MXS0JJRwKDViZHH5dy=>	MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiNDD0c{A2KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOzZwN{[g{txONg>?	Ml3jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
HEK293	NECxXnpHfW6ldHnvckBie3OjeR?=		MWW1JI1qdnN?	M3;PNmlvcGmkaYTpc44hd2ZiaIXtZY4hdGm4ZYKgU2FVWDGEMzDlfJBz\XO\|ZXSgbY4hUEWNMkmzJGZteC2LbjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hYzOKXVWxO{1j\XSjRzD1dJRic2ViaX7jeYJifGWmIH\vdkA2KG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygT4khRSB2MTFOwG0tKEmFNUCgQUA1PCEQvF2u	MojnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
RXF 393NL	M1HPU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NGrYd281KGSjeYO=	MofxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnhHKDN7M17MJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDR3Lk[g{txONg>?	NHTuW5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
LIXF 575L	MXPDfZRwfG:6aXPpeJkh[XO\|YYm=		MlS3OEBl[Xm\|	Mn3vR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUGlZTiB3N{XMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDR5LkKg{txONg>?	NUPBXnY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
NCI-H23	M3:4fmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFzZSmw1PiCqcoO=	MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB2NjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNEmuN{DPxE1w	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF\|OECyO{c,OjlzM{iwNlc9N2F-
polycythemia vera hematopoietic progenitor cell	NULHSYg4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MmOyOUB2VQ>?		M{DINmdzd3e2aDDpcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5NqdmdiaIXtZY4heG:ueXP5eIhmdWmjII\ldoEhcGWvYYTvdI9q\XSrYzDwdo9o\W6rdH;yJINmdGy\|IHH0JFUhfU1iYomg[ZJ6fGi{b3nkJIJ2enO2LX\vdo1qdmdidX7peEBie3OjeTygUnVNVCB;IF7VUGwh\|ryPLh?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF5OEeyNkc,OTdzN{i3NlI9N2F-
A431	M{fVSGZ2dmO2aX;uJIF{e2G7		MXexJIhzew>?	NWThU4Q5UW6qaXLpeIlwdiCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCDNEOxJINmdGy\|IIDy[ZRz\WG2ZXSg[o9zKDFiaILzJIZwdGyxd3XkJIJ6KEWJRj3zeIlufWyjdHnvckBjgSCrbX31co9jdG:2IHHuZYx6e2m\|LDDOWWxNKD1iTmXMUEDPxE1w	NIXV[W09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2PVQ3PSd-MUm5Olk1PjV:L3G+
PC9	M{\6ZWN6fG:2b4jpZ4l1gSCjc4PhfS=>	M3LubFAvODBzIITvJFExKHWP	MVu5OkBpenN?	MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|kh[2WubIOg[ZhxemW\|c3nu[{A4PDZvN{WwJJNmeXWnbnPlJIRmdGW2ZXSgSWdHWiCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjdDCwMlAxOSC2bzCxNEB2VSCjZoTldkA6PiCqcoOgZpkh[2WubDD0bZRmei2pbH:gZZN{[XluIF7VUGwhRSCQVVzMJO69VS5?	NXW2PIxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
NCI-H1975	NYnSZ4RTS3m2b4TvfIlkcXS7IHHzd4F6	NHHCfVMxNjByMTD0c{AyOCC3TR?=	M{LaWlk3KGi{cx?=	MlPaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHX4dJJme3OrbnegSWdHWiCWN{mwUUBidmRiTEi1PHIhdXW2YX70JIF1KDBwMECxJJRwKDFyIIXNJIFnfGW{IEm2JIhzeyCkeTDj[YxtKHSrdHXyMYdtdyCjc4PhfUwhVlWOTDC9JG5WVExizszNMi=>	NV;XboFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
Huh7.5	Mm\JRY51cX[rcnHsJIF{e2G7		M1zOfFMxKG2rboO=	M1y5bGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhmeGG2aYTpd{BEKH[rcoXzJGo3N0qISDDpcoZm[3SnZDDpckBpfW2jbjDIeYg4NjViY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJS1ZicnXwcIlk[XSrb36gdJJmfHKnYYTl[EBnd3JiM{CgcYlveyCob3zsc5dm\CCkeTDpcoZm[3Srb36gcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIR6\SCkYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEGldHn2bZR6KD1iTmXMUEDPxE1w	NFHJd3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmyOVIxQCd-Mk[5NlUzODh:L3G+
A673	MlGzdWhVWyCjc4PhfS=>			M2LiOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|LDDOWWxNKD1iTmXMUEDPxE1w	NUDRXmpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	MoPxdWhVWyCjc4PhfS=>			MonRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	NWnrR29TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MmXHdWhVWyCjc4PhfS=>			NGXRUlZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIOsJG5WVExiPTDOWWxNKM7:TT6=	NU[5b2wyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MVnxTHRUKGG\|c3H5			MlrSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|LDDOWWxNKD1iTmXMUEDPxE1w	NVfybVA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MV;xTHRUKGG\|c3H5			MkHUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	MorRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MkjodWhVWyCjc4PhfS=>			NVH4[FZ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MXnxTHRUKGG\|c3H5			M2[xVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|LDDOWWxNKD1iTmXMUEDPxE1w	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	NXXtbI5EeUiWUzDhd5NigQ>?			NXzqWlNjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHNuIF7VUGwhRSCQVVzMJO69VS5?	NFnCSGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NHfpUm9yUFSVIHHzd4F6			MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	NWrpU4dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NXT0[IU3eUiWUzDhd5NigQ>?			MnHPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	NUP1bnA5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	MmPldWhVWyCjc4PhfS=>			NInURoZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	Mn7jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NYHS[pZ4eUiWUzDhd5NigQ>?			NHGxN49yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	M1ntZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	M1\GcJFJXFNiYYPzZZk>			NVLrWJhIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJMtKE6XTFygQUBPXUyOIN88UU4>	M2\ZNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NXrLPVdbeUiWUzDhd5NigQ>?			M4O0fJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MnnmdWhVWyCjc4PhfS=>			NVPMUGZoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIOsJG5WVExiPTDOWWxNKM7:TT6=	MlTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MVnxTHRUKGG\|c3H5			NV3J[pYxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	NHnNWos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	MUfxTHRUKGG\|c3H5			NGfxZ4FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{NCCQVVzMJF0hVlWOTDFOwG0v	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
HCC827	NI\oTIlCeG:ydH;zbZMh[XO\|YYm=	M1HC[VEhfU1?	MlewNlQhcHK\|	MWXJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDheEAyKHWPIHHmeIVzKDJ2IHjyd{B2e2mwZzDwdo9xcWSrdX2gbY9lcWSnIHL5JIZtd3diY4n0c41mfHK7LDDOWWxNKD1iTmXMUEDPxE1w	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNEc,OjR7MEC4N\|A9N2F-
NCI-H1648	NH7WUY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NInHTWJKSzVyIE2gNE4xPDByMjFOwG0>	MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-12	NX\UcGdFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NX\De255UUN3MDC9JFAvODV2NEGg{txO	NXLzO2t5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ECC12	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NEexeVJKSzVyIE2gNE4xQDB3MjFOwG0>	NH3oW4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
BB30-HNC	MmrNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NUn5PXR4UUN3MDC9JFAvOTR5NkWg{txO	NIXFO449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
LB996-RCC	M1P2WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NY\N[W55UUN3MDC9JFAvPDBzNkGg{txO	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
EW-24	MoPxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NHXHSZRKSzVyIE2gNE42QTR2MzFOwG0>	M1XsTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LC-1F	NX\wPIROT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M4DjSGlEPTBiPTCwMlYxPjN{IN88US=>	M4jt[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TK10	M2TvVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M2CyNGlEPTBiPTCwMlg2QDd6IN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
A388	M2nNUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NFq5VmRKSzVyIE2gNU4xQTN6IN88US=>	NXrVdlBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
EKVX	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXzJR\|UxKD1iMT6xNlM2PCEQvF2=	M3zqflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-9	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M4PoSWlEPTBiPTCxMlIzPTFzIN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TE-1	MmTxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NH6xSXNKSzVyIE2gNU41ODR6IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MOLT-16	MmfqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Ml3mTWM2OCB;IEGuPVI6OjVizszN	NWXSWWxyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
TE-6	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MWLJR\|UxKD1iMj61Olc5KM7:TR?=	NGjUTI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
697	Ml;RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M2jMRWlEPTBiPTCyMlY2OzB3IN88US=>	M4rUSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
A253	NUD4[XFsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M{jaZ2lEPTBiPTCyMlc2OTZizszN	NWq2cJJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
OS-RC-2	M{XV[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NHT5ZmRKSzVyIE2gNk46PDB{MzFOwG0>	MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
KS-1	NUjwfpVuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NFrrblJKSzVyIE2gNk46PDV2MjFOwG0>	NUTyN\|h2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MC116	Ml\yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NGPwSYlKSzVyIE2gN{43OjB2OTFOwG0>	M2HXPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LB2241-RCC	M{TmcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MlXUTWM2OCB;IEOuPFE4OjlizszN	NX7VeIYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
RL95-2	M3q2emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NFjwO2RKSzVyIE2gOE4xOzN{IN88US=>	NHWwdXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
HCE-T	MmizS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NHniVItKSzVyIE2gOE4yODF6ODFOwG0>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NCCIT	MmTvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MoLmTWM2OCB;IESuN\|g1QTdizszN	Mn\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
GCIY	MkPHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MlyzTWM2OCB;IESuOlM2OzJizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LB1047-RCC	M4Huemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M3rCe2lEPTBiPTC0Mlk5Ozd7IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
A3-KAW	M4XObmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWTJR\|UxKD1iNT60N\|k1PiEQvF2=	M3zweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-15	NH2zXZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M2jSO2lEPTBiPTC1MlQ4OjdizszN	NIPSbZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NOS-1	M1HodWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NITFNohKSzVyIE2gOU41QTN6NjFOwG0>	NV7N[IdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
EW-16	Mn;2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M3q4dGlEPTBiPTC2MlI2Ozh5IN88US=>	NXn1dIhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LAMA-84	MnrFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MYHJR\|UxKD1iNz6wNFc4OiEQvF2=	MkjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-5	M3nGWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MYnJR\|UxKD1iNz6wOFI1PyEQvF2=	NX7uOXlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HEL	NGez[25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1PXcGlEPTBiPTC3MlM{PTZ2IN88US=>	NWSxcXNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NCI-H209	MoPWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NE\uNYNKSzVyIE2gPE4xPDRzMjFOwG0>	M2PzZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
DJM-1	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MV7JR\|UxKD1iOD61Nlk3PCEQvF2=	M4LLdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
OVCAR-4	MmLpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MofVTWM2OCB;IEiuPFQzOTlizszN	MkfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NB17	NYDvbpYyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M33yfGlEPTBiPTC5MlI2QTlzIN88US=>	NVPtZooxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	M33wS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M2n3fWlEPTBiPTC5MlM2Pzd4IN88US=>	NFvoZoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB5	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MWLJR\|UxKD1iMUCuNlkh\|ryP	NHS3[2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
BV-173	NY\GWlN{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NHnhNIVKSzVyIE2gNVAvOzJ5MjFOwG0>	MofUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MPP-89	NWX4cnlDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NHLNPYVKSzVyIE2gNVAvPDR{IN88US=>	NIf5dnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
RPMI-6666	NWLN[VFsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MmXHTWM2OCB;IEGwMlQ6PjlizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MS-1	M4[4SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MoLTTWM2OCB;IEGxMlQ3PThizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
ALL-PO	M1nMd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MYLJR\|UxKD1iMUGuOVE4QSEQvF2=	MmjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NB10	NUHNN4E1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MY\JR\|UxKD1iMUGuO\|U5PyEQvF2=	M3rLclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB13	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M4HV[GlEPTBiPTCxNU46QTF2IN88US=>	NGHrRpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SCH	MnXJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MmTWTWM2OCB;IEGyMlE5QTFizszN	MknMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ES6	NVnQRXJTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NVXiRY1xUUN3MDC9JFEzNjR5NTFOwG0>	M{mzT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
ETK-1	NGq4OohIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M4PnSGlEPTBiPTCxOE4xQDh3IN88US=>	NWfreZJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ES4	MknpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NYizUVlpUUN3MDC9JFE1Njh2NEWg{txO	NUfyPWhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
K-562	M3nXS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MUPJR\|UxKD1iMUWuPFE1KM7:TR?=	M1;PdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
D-502MG	Ml;6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M1f0SWlEPTBiPTCxO{4{PDZ6IN88US=>	MnfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LB647-SCLC	M{\HdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MUnJR\|UxKD1iMUeuO\|czPiEQvF2=	NHTlTVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
TE-10	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NF;lR5ZKSzVyIE2gNVgvOTF\|ODFOwG0>	M4XQd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MZ1-PC	MnzvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MUHJR\|UxKD1iMUiuN\|c4PCEQvF2=	MkDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
CTB-1	NH\LUZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MYXJR\|UxKD1iMUiuOVA4PSEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NMC-G1	MmHSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NETTc2RKSzVyIE2gNVgvQDB{OTFOwG0>	Mnj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
C2BBe1	NV;jWmxHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NV3TSWRVUUN3MDC9JFE5Njh4NkSg{txO	NWTqPG9mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M{DuTWlEPTBiPTCxPU42PDh{IN88US=>	NFfwXFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
HCC2157	M174Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MXTJR\|UxKD1iMkCuN\|M3OSEQvF2=	NF;DbHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
Becker	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M4rjTmlEPTBiPTCyNE4{PTRzIN88US=>	NUjv[YIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ST486	M4XaS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NGftRVhKSzVyIE2gNlAvPDB7MzFOwG0>	M4X3ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LC-2-ad	M{HEfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NHL0eoxKSzVyIE2gNlAvQTZ\|NzFOwG0>	NILHd3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H747	NEW1Z3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MVfJR\|UxKD1iMkGuOVE{QSEQvF2=	M{TDblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
BE-13	NELYOIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MoH0TWM2OCB;IEKxMlgyPThizszN	NXTzOGVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
no-11	NWr1Wnc{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NYjIRVZuUUN3MDC9JFIyNjlzME[g{txO	NWDoU3dyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
TE-8	NFXuSlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MoLtTWM2OCB;IEKyMlY{OThizszN	M1nLUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB6	Mm\IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NGK5eWVKSzVyIE2gNlIvQDNyMzFOwG0>	M2XkNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
BB65-RCC	NWez[2xmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MYjJR\|UxKD1iMkKuPVYzOyEQvF2=	NUC0bo9FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SK-UT-1	MlXnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MV7JR\|UxKD1iMkOuNVQ6PyEQvF2=	MlHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
D-392MG	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXnJR\|UxKD1iMkSuNlk{PCEQvF2=	NV7vfFd2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
JVM-2	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M3;wZ2lEPTBiPTCyOE42OzN\|IN88US=>	NX3YWZlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SW954	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M4DoeGlEPTBiPTCyOE42QTF4IN88US=>	M3zpWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
QIMR-WIL	Mlv1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Mn6xTWM2OCB;IEK1MlE6PzNizszN	M{m5S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MEG-01	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NGXUUnZKSzVyIE2gNlUvQTBzNjFOwG0>	NFnOWnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
A101D	Mn7rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NHTJboxKSzVyIE2gNlgvPzF\|OTFOwG0>	M4\yWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LB831-BLC	M1XoUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M1LmPWlEPTBiPTCzNE41ODB2IN88US=>	NYricJlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
KGN	M2Pubmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MojwTWM2OCB;IEOwMlg3PjFizszN	NYLGbHlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HC-1	NHezfJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NXTTb5EzUUN3MDC9JFMyNjN3MEig{txO	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
CP66-MEL	MoHQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MYXJR\|UxKD1iM{GuPFM3PiEQvF2=	M{e3PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
D-542MG	NXTHR41rT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M336RWlEPTBiPTCzNk41OzN5IN88US=>	NFjUcWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
LS-513	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NFGzeFhKSzVyIE2gN\|MvPDh2NDFOwG0>	MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
DOHH-2	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MVTJR\|UxKD1iM{OuOlU5QSEQvF2=	MlzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NB69	MkjYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MknjTWM2OCB;IEOzMlkzODZizszN	NWDsb\|M4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SW962	NVy4WYd1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MkS2TWM2OCB;IEO1MlczOTdizszN	NEXTS249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	MljDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MVjJR\|UxKD1iM{[uNFczPCEQvF2=	NYHQ[ndtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MONO-MAC-6	NHK5R\|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MlXkTWM2OCB;IEO2MlU{PTlizszN	NGPUZpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MLMA	NWiwSHBYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M{LSd2lEPTBiPTCzPE43PTJizszN	NWr4S\|BURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HOP-62	MlGzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NXPGe29xUUN3MDC9JFM6NjF5NkWg{txO	MkK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LP-1	MoS4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NILFUWJKSzVyIE2gN\|kvPDRzNTFOwG0>	NH72WGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
ONS-76	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M3izUGlEPTBiPTCzPU46OTV{IN88US=>	MmfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
KNS-42	Mn2yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MnHqTWM2OCB;IESwMlA2OzFizszN	M4CydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NCI-H1581	M4n0S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NUj0SYFsUUN3MDC9JFQyNjF6NEKg{txO	M3[yZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
DSH1	Mm\lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MoDhTWM2OCB;IESyMlQxPyEQvF2=	M{W5blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NCI-H1355	NHT2TItIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1;jVWlEPTBiPTC0Nk45OzlizszN	MkT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
D-247MG	M1jXWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NX3Vd5RVUUN3MDC9JFQ2NjdzOTFOwG0>	M2DON\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MC-CAR	MmLyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MVPJR\|UxKD1iNEWuPVY6OSEQvF2=	NHLGSIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
EW-1	NYP0UWJIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NUfNe2ExUUN3MDC9JFQ4NjV4MkSg{txO	NVv4dJA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
GI-ME-N	NGTseHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M3OwWmlEPTBiPTC0PE4yOzh2IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
BT-474	NUXG[4lwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M1nudGlEPTBiPTC0PE4yPzN6IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LB373-MEL-D	MkTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NETkWYFKSzVyIE2gOFgvPzV4MzFOwG0>	NVG1fYl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Met / Met / p-Axl / Axl / pERK / ERK / pEGFR / EGFR / p-STAT3 / STAT3 / p-Akt / Akt; PubMed: 28604685 Nat Neurosci (b) Patient derived primary GBM neurospheres (GBM9) were exposure to erlotinib (1µM) for the indicated times followed by Western blot with the indicated antibodies. (c–d) A similar experiment in patient derived GBM neurospheres from two different patients (GBM39 and SK987). (e) U87EGFR cells were treated with erlotinib (1µM) for the indicated times followed by Western blot with the indicated antibodies. (f) Similar experiment was conducted in U87EGFRvIII cells. p-Raf-1 / Raf-1 / p-MEK / MEK; PubMed: 27508092 Am J Cancer Res Cells from both ER and ECR groups were treated with 3 μM erlotinib for 72 h. Cell lysates were used for Western blotting with indicated antibodies. cleaved PARP / PARP; PubMed: 27508092 Am J Cancer Res HCC827 or H1650 cells were treated with DMSO, celecoxib, erlotinib alone, or in combination for 48 h. Western blot analysis showed that cleaved PARP was higher in cells after combination treatment. p27 / pS10-p27 / pT157-p27 / pT187-p27; PubMed: 21045138 Mol Cancer Ther BT-474 and SK-BR-3 cells were treated with erlotinib at 0, 1, or 3 µM for 72 h, after which expression of total p27, p27 phosphorylated at S10 (pS10-p27), pT157-p27, and pT187-p27 was assessed by western blot analysis. β-actin was used as a loading control. Bcl-2 / Bcl-xl / Mcl-1 / Bax / Bak / Bad / Bim EL / PUMA; PubMed: 17927446 PLoS Med Effects of erlotinib treatment on proapoptotic and antiapoptotic proteins in H3255 cells. H3255 cells were treated with different concentrations of erlotinib for 24 h. Cell lysates were examined by immunoblotting using antibodies specific for the indicated proteins.	28604685 27508092 21045138 17927446
Immunofluorescence	Bax / Cyto C; PubMed: 17927446 PLoS Med Erlotinib induces colocalization of BAX and cytochrome c in PC-9 cells undergoing apoptosis. Cells were grown in Lab-Tek II chambers and treated with 100 nM erlotinib or DMSO for 48 h, fixed and immunostained with antibodies against BAX (green) and cytochrome c (red) or with DAPI to detect DNA (blue). Cells were imaged by confocal microscopy. E-cadherin / β-catenin / Vimentin; PubMed: 19825949 Clin Cancer Res SUM149 cells were plated in 3D culture without or with erlotinib for 4 days. Immunofluorescence analysis was performed to detect E-cadherin, β-catenin, and vimentin. Nuclei were visualized with DAPI. EGFR ; PubMed: 27612423 Oncotarget HCC827 (delE746-A750), NCI-H3255 (L858R) and NCI-H1975 (L858R/T790M) cells were treated either with DMSO (control) or with 3 μM erlotinib/200 nM AZD9291 for the indicated time points. Cells were fixed and stained with EGFR antibody (red) and DAPI (blue, DNA dye) as described in the Materials and Methods. Representative images showing decreased EGFR immunofluorescence in erlotinib-sensitive HCC827 and NCI-H3255 cells. AZD9291 also reduced EGFR immunofluorescence even in NCI-H1975 cells. Scale bars, 10 μm.	17927446 19825949 27612423
Growth inhibition assay	Cell viability; PubMed: 30377412 Cancer Cell Int a The MTT assay for PANC-1 viability. Different doses of erlotinib were added to the medium of PANC-1 cells. b LDH release was used to evaluate the cell death in PANC-1 cells in the presence of erlotinib. c The MTT assay for PaCa-2 cells in the presence of erlotinib treatment. d LDH release was used to evaluate the cell death in PaCa-2 cells in the presence of erlotinib.	30377412

In vivo

At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. ^[1] Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate. ^[5]

Protocol

Kinase Assay:^[1]	- Collapse Kinase assays: 96-well plates are coated by incubation overnight at 37 °C with 100 μL per well of 0.25 mg/mL PGT in PBS. Excess PGT is removed by aspiration, and the plate is washed 3 times with washing buffer (0.1% Tween 20 in PBS). The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3), containing 125 mM sodium chloride, 24 mM magnesium chloride, 0.1 mM sodium orthovanadate, 20 μM ATP, 1.6 μg/mL EGF, and 15 ng of EGFR, affinity purified from A431 cell membranes. Erlotinib HCl in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 minutes at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with washing buffer. Phosphorylated PGT is measured by 25 minutes of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with washing buffer. The colonmetric signal is developed by addition of TMB Microwell Peroxidase Substrate, 50μL per well, and stopped by the addition of 0.09 M sulfuric acid, 50 μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no back ground in wells without AlP, EGFR, or PGT and is proportional to the time of incubation for 10 minutes.
Cell Research:^[2]	- Collapse Cell lines: A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 cells Concentrations: 30 nM-20 μM Incubation Time: 72 hours Method: Exponentially growing cells are seeded in 96-well plastic plates and exposed to serial dilutions of erlotinib, pemetrexed, or the combination at a constant concentration ratio of 4:1 in triplicates for 72 h. Cell viability is assayed by cell count and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Growth inhibition is expressed as the percentage of surviving cells in drug-treated versus PBS-treated control cells (which is considered as 100% viability). The IC50 value is the concentration resulting in 50% cell growth inhibition by a 72-h exposure to drug(s) compared with untreated control cells and is calculated by the CalcuSyn software. (Only for Reference)
Animal Research:^[6]	- Collapse Animal Models: Male 5-week-old BALB-nu/nu with HPAC cells Dosages: 50 mg/kg Administration: Oral administration (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.3 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 15% Captisol For best results, use promptly after mixing.	16 mg/mL warmed (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Erlotinib HCl (OSI-744) SDF

Molecular Weight	429.90
Formula	C₂₂H₂₃N₃O₄.HCl
CAS No.	183319-69-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CP358774, NSC 718781
Smiles	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04172779	Not yet recruiting	Drug: Erlotinib Hydrochloride	Cirrhosis Liver	University of Texas Southwestern Medical Center	July 2021	Phase 2
NCT03460678	Terminated	Drug: Pemetrexed\|Drug: Erlotinib	Carcinoma Non-Small-Cell Lung	Hikma Pharmaceuticals LLC	February 28 2018	Phase 4
NCT02942095	Active not recruiting	Drug: Ixazomib\|Drug: Erlotinib	Solid Tumors	M.D. Anderson Cancer Center\|Millennium: The Takeda Oncology Company	March 6 2017	Phase 1
NCT02991651	Recruiting	Drug: IRX4204\|Drug: erlotinib	Lung Cancer Nonsmall Cell	Io Therapeutics\|Dartmouth College	May 2016	Phase 1
NCT02762877	Terminated	--	Non Small Cell Lung Carcinoma	Genomic Health® Inc.	April 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether S1023 is suitable for mouse assays?
Answer:
Dissolving S1023 in 15% Captisol is for oral gavage and it's a suspension.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib (CP358774, NSC 718781, OSI-774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib (GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Erlotinib HCl (OSI-744)